WO2004033434A1 - Pyrazole compounds for treatment of neurodegenerative disorders - Google Patents

Pyrazole compounds for treatment of neurodegenerative disorders Download PDF

Info

Publication number
WO2004033434A1
WO2004033434A1 PCT/IB2003/004252 IB0304252W WO2004033434A1 WO 2004033434 A1 WO2004033434 A1 WO 2004033434A1 IB 0304252 W IB0304252 W IB 0304252W WO 2004033434 A1 WO2004033434 A1 WO 2004033434A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
pyrazol
acetylamino
difluoro
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2003/004252
Other languages
French (fr)
Inventor
Martin Patrick Allen
Yuhpyng L. Chen
Spiros Liras
Robert L. Rosati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Priority to BR0315158-1A priority Critical patent/BR0315158A/en
Priority to CA002501799A priority patent/CA2501799C/en
Priority to AU2003263518A priority patent/AU2003263518A1/en
Priority to MXPA05003432A priority patent/MXPA05003432A/en
Priority to EP03807922A priority patent/EP1551809A1/en
Priority to JP2004542713A priority patent/JP2006504725A/en
Publication of WO2004033434A1 publication Critical patent/WO2004033434A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention relates to treatment of Alzheimer's disease and other neurodegenerative disorders in mammals, including in humans.
  • This invention also relates to inhibiting in mammals, including in humans, the production of ⁇ -amyloid peptides (A ⁇ - peptides) which can contribute to formation of neurological deposits of amyloid protein.
  • a ⁇ - peptides ⁇ -amyloid peptides
  • this invention relates to pyrazole compounds useful for treatment of neurological disorders, such as Alzheimer's disease and Down's Syndrome, related to A ⁇ -peptide production.
  • AD Alzheimer's disease
  • CAA cerebral amyloid angiopathy
  • prion-mediated diseases see, e.g., Haan et al. Clin. NeuroL Neurosurg. 1990, 92(4):305-310; Glenner et al. J Neurol. Sci. 1989, 94:1-28).
  • AD affects nearly half of all people past the age of 85, the most rapidly growing portion of the United States population. As such, the number of AD patients in the United States is expected to increase from about 4 million to about 14 million by the middle of the next century.
  • AD Alzheimer's disease
  • Stimulated memory exercises on a regular basis have been shown to slow, but not stop, memory loss.
  • a few drugs, for example AriceptTM, provide treatment of AD.
  • AD Alzheimer's disease
  • amyloid A ⁇ -peptides also called A ⁇ -peptides, which consist of three proteins having 40, 42 or 43 amino acids, designated as the A ⁇ - o , A ⁇ , and A ⁇ peptides, respectively.
  • the A ⁇ -peptides are thought to cause nerve cell destruction, in part, because they are toxic to neurons in vitro and in vivo.
  • the A ⁇ peptides are derived from larger ⁇ -amyloid precursor proteins (APP proteins), which consist of four proteins containing 695, 714, 751 or 771 amino acids, designated as the APP 695 .
  • APP 7 ⁇ , APP 75 ⁇ and APP 771 respectively.
  • proteases are believed to produce the A ⁇ peptides by cleaving specific amino acid sequences within the various APP proteins.
  • the proteases are named "secretases” because the A ⁇ -peptides they produce are secreted by cells into the extracellular environment. These secretases are each named according to the cleavage(s) they make to produce the A ⁇ -peptides.
  • APP is cleaved by alpha- and beta- secretases, causing the release of soluble derivatives of protein ( ⁇ -APPs and ⁇ -APPs) and the retention of membrane-bound 83- and 99-amino acid fragments (C83 and C99). These fragments are substrates for the enzyme gamma-secretase.
  • Gamma-secretase produces the A ⁇ -peptide fragment from C99 and p3 from C83.
  • Gamma-secretase and beta-secretase inhibitors are thus expected to inhibit the production of A ⁇ - peptide.
  • This invention relates to novel compounds that inhibit A ⁇ -peptide production, to pharmaceutical compositions comprising such compounds, and to methods of using such compounds to treat neuorodegenerative disorders. Summary of the Invention
  • the present invention provides compounds of Formula:
  • R 1 is selected from C C 20 alkyl and -C C 20 alkoxy, C 3 -C 8 cycloalkyl, (C 4 -
  • -C 4 -C 8 cycloalkenyl, -(C 5 -C ⁇ )bi- or tricycloalkyl, -(Cr-C ⁇ bi- or tricycloalkenyl, -(3-8 membered) heterocycloalkyl, -(C 6 -C 14 )aryl, -(5-14 membered) heteroaryl, -(C 6 -C 14 ) aryloxy, and -(5-14 membered) heteroaryloxy, wherein said alkyl, alkoxy, cycloalkyl, cycloalkenyl, bi- or tricycloalkyl, bi- or tricycloalkenyl, heterocycloalkyl, aryl, heteroaryl, aryloxy, and heteroaryloxy are each independently optionally substituted with from one to three R 1b substituents;
  • R 3 is selected from C 1 -C 6 alkyl, -C 2 -C 6 alkenyl, -C 2 -C 6 alkynyl, -(C zer0 -C 4 alkylene)- (C 3 -C 6 cycloalkyl), and -(C zero -C 4 alkylene)-(C 3 -C 6 cycloalkenyl), wherein said alkyl, alkenyl and alkynyl are each optionally substituted with a substituent selected from -OH, C C alkoxy, and -S-(C r C 4 alkyl); R 4 is H, D, F, or C,-C 4 alkyl; or R 3 and ⁇ R 4 may together optionally form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, morpholino, piperidino, or perhydro-2H-pyran moiety, wherein said moiety formed by R 3 and R 4
  • alkyl independently optionally containing from one to three double or triple bonds
  • -C ⁇ -C 6 alkoxy independently optionally containing from one to three double or triple bonds
  • R 11 and R 12 are each independently selected from H, -C C 6 alkyl, -(C zero -C 4 alkylene)- (C 3 -C 8 cycloalkyl), -(C zero -C 4 alkylene)-(C 4 -C 8 cycloalkenyl), -(C zero -C 4 a!kylene)-((C 5 -C 1 )bi- or tricycloalkyl), and -(C zer0 -C 4 alkylene)-((C -C 11 )bi- or tricycloalkenyl), -(C zera -C alkylene)-(C 6 - C 10 aryl), -(C zero -C 4 alkylene)-((3-8 membered) heterocycloalkyl), and -(C zero -C 4 alkylene)-((5- 14 membered) heteroaryl), and R 11 and R 12 are independently optionally substituted with from one to three R
  • Compounds of Formula I inhibit production of A ⁇ -peptide.
  • Compounds of Formula I and their pharmaceutically acceptable salts are therefore useful in treating neurodegenerative disorders, for example AD, in mammals, including humans.
  • the present invention provides compounds of Formula I wherein
  • the invention provides compounds of Formula I wherein R 3 is C C 4 alkyl wherein each hydrogen is independently optionally replaced with a fluorine.
  • R 3 is allyl.
  • R 3 is methyl, ethyl, n-propyl, n-butyl, /-butyl, s-butyl, or -CH 2 CH 2 SCH 3 .
  • the present invention provides compounds of Formula I wherein R 6 is selected from hydrogen, methyl, ethyl, -F, -CI, -Br, and -CF 3 .
  • the present invention provides compounds of Formula I wherein R 1 is -C 2 -C ⁇ 2 alkyl, C 3 -C 8 cycloalkyl, (C 5 -C 8 )cycloalkenyl, -(d-C ⁇ bi- or tricycloalkyl, -(C 7 -Cn)bi- or tricycloalkenyl, (3-8 membered) heterocycloalkyl), -(C 6 -C 10 )aryl, -(5-10 membered) heteroaryl, or C C 4 alkyl substituted with R a wherein R 1a is -(C 6 -C 10 )aryl or -(5-
  • the present invention provides compounds of Formula I wherein R 1 is C 2 -C 10 alkyl, C 3 -C 10 cycloalkyl, or -(C T -CnJbicycloalkyl, wherein said alkyl optionally contains from one to five double bonds, and wherein each hydrogen atom of said alkyl may optionally be replaced with a fluorine.
  • R 1 is C 2 -C 0 alkyl
  • R 1 is straight-chain.
  • R 1 is branched C 3 -C 10 alkyl.
  • R is C 3 -C 10 alkyl comprising a tertiary carbon, for example /- propyl or 2-methylpropyl.
  • R 1 is C 4 -C 10 alkyl comprising a quaternary carbon, for example t-butyl.
  • R 1 is selected from phenyl, thienyl, and pyridyl, optionally and independently substituted with one or two substituents R 1b .
  • each R 1b is preferably independently selected from -C C 4 alkyl (in different embodiments, independently optionally containing one or two double or triple bonds), CF 3 , -C C 4 alkoxy (in different embodiments, independently optionally containing one or two double or triple bonds), -F, -CI, -Br, phenyl, and phenoxy.
  • R 1 is phenyl or pyridyl and is optionally substituted with one or two substituents R 1b independently selected from -F, -CI and -CF 3 .
  • R 3 is preferably C C 4 alkyl, for example methyl, ethyl, /.-propyl, n-butyl, /-butyl, s-butyl, or R 3 is allyl or -CH 2 CH 2 SCH 3 , and R 6 is preferably hydrogen, methyl, ethyl, -F, -CI, -Br, and -CF 3 .
  • Z is -CH 2 - or -CH(OH)-;
  • R 3 is C r C alkyl wherein each hydrogen is independently optionally replaced with a fluorine, or R 3 is allyl or -CH 2 CH 2 SCH 3 ;
  • R 6 is selected from hydrogen, methyl, ethyl, -F, -CI, -Br, and -CF 3 ; and
  • R 1 is -C 2 -C 2 alkyl, C 3 -C 8 cycloalkyl, (C 5 -C 8 )cycloalkenyl, -(C 5 -Cn)bi- or tricycloalkyl, -(C 7 -Cn)bi- or tricycloalkenyl, -((3-8 membered) heterocycloalkyl), -(C 6 -C 10 )aryl, -(
  • Z is -CH 2 - or -CH(OH)-;
  • R 3 is C C 4 alkyl wherein each hydrogen is independently optionally replaced with a fluorine, or R 3 is allyl or -CH 2 CH 2 SCH 3 ;
  • R 6 is selected from hydrogen, methyl, ethyl, -F, -CI, -Br, and -CF 3 ; and
  • R 1 is C 3 -C 10 alkyl comprising a tertiary carbon, for example /-propyl or 2- methylpropyl, or
  • R 1 is C 4 -C 10 alkyl comprising a quaternary carbon, for example t-butyl.
  • Z is -CH 2 - or -CH(OH)-;
  • R 3 is C 1 -C alkyl wherein each hydrogen is independently optionally replaced with a fluorine, or R 3 is allyl or -CH 2 CH 2 SCH 3 ;
  • R 6 is selected from hydrogen, methyl, ethyl, -F, -CI, -Br, and
  • R 1 is selected from phenyl, thienyl, and pyridyl, optionally and independently substituted with one or two substituents R 1b , preferably independently selected from -C- ⁇ -C 4 alkyl, CF 3 , -C 1 -C 4 alkyoxy, -F, -CI, -Br, phenyl, and phenoxy.
  • Z is -CH 2 - or -CH(OH)-;
  • R 3 is C ⁇ -C 4 alkyl wherein each hydrogen is independently optionally replaced with a fluorine, or R 3 is allyl or -CH 2 CH 2 SCH 3 ;
  • R 6 is selected from hydrogen, methyl, ethyl, -F, -CI, -Br, and -CF 3 ;
  • R 1 is phenyl or pyridyl and is optionally substituted with one or two substituents R b independently selected from -F, -CI and -CF 3 .
  • Z is -CH 2 - or -CH(OH)-;
  • R 3 is C C alkyl wherein each hydrogen is independently optionally replaced with a fluorine, or R 3 is allyl or -CH 2 CH 2 SCH 3 ;
  • R 6 is selected from hydrogen, methyl, ethyl, -F, -CI, -Br, and -CF 3 ; and
  • R 1 is C 3 -C 7 cycloalkyl, for example [2.2.1]-heptanyl.
  • R 7 is selected from -C C 2 alkyl optionally containing from one to five double bonds and wherein each hydrogen is independently optionally replaced with a fluorine, -(C 3 -C 12 ) cycloalkyl optionally substituted with from one to six fluorine and -((3- 12 membered) heterocycloalkyl) optionally substituted with from one to six fluorine, wherein said alkyl, cycloalkyl and heterocycloalkyl are each optionally substituted with from one to three substitutents independently selected from -OH, -C C 6 alkoxy independently optionally containing from one to three double or triple bonds, -NR 9 R 10 , -(CH 2 ) 1 .
  • the invention provides compounds of Formula I wherein R 7 is selected from -C r C ⁇ 2 alkyl optionally containing from one to five double bonds, -(C 3 -C 12 ) cycloalkyl and -((3-12 membered) heterocycloalkyl), wherein said alkyl, cycloalkyl and heterocycloalkyl are each optionally substituted with from one to three substitutents independently selected from -OH, -CrC 6 alkoxy independently optionally containing from one to three double or triple bonds, -NR 9 R 10 , and -(CH 2 ) 1 . 6 NR 9 R 10 .
  • R 7 is selected from -C C 12 alkyl optionally containing from one to five double bonds, -(C 3 -C 12 ) cycloalkyl and -(3-12 membered) heterocycloalkyl, wherein said alkyl, cycloalkyl and heterocycloalkyl are each optionally substituted with from one to three substitutents independently selected from -OH and -C C 6 alkoxy independently optionally containing from one to three double or triple bonds.
  • R 7 is selected from -C ⁇ -C 12 alkyl optionally containing from one to five double bonds and -C 3 -C 15 cycloalkyl, wherein said alkyl and cycloalkyl are each optionally independently substituted with from one to three substitutents -NR 9 R 10 .
  • R 7 is -((3-12 membered) heterocycloalkyl), wherein said heterocycloalkyl is optionally substituted with from one to three substitutents independently selected from -OH, -C C 6 alkyl independently optionally containing from one to three double or triple bonds, -CrC 6 alkoxy independently optionally containing from one to three double or triple bonds, -(C 6 -C 10 ) aryl, and -(5-15 membered) heteroaryl.
  • halogen halo, and the like, as used herein, unless otherwise indicated, include F, CI, Br, and I.
  • alkyl as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight or branched moieties.
  • alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, and .-butyl.
  • alkenyl as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon double bond wherein alkyl is as defined above. Examples of alkenyl include, but are not limited to, ethenyl and propenyl.
  • alkynyl as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon triple bond wherein alkyl is as defined above. Examples of alkynyl groups include, but are not limited to, ethynyl and 2-propynyl.
  • cycloalkyl includes non- aromatic saturated cyclic alkyl moieties wherein alkyl is as defined above.
  • examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
  • Bicycloalkyl and tricycloalkyl groups are non-aromatic saturated carbocyclic groups consisting of two or three rings respectively, wherein said rings share at least one carbon atom.
  • bicycloalkyl groups include spiro groups and fused ring groups.
  • bicycloalkyl groups include, but are not limited to, bicyclo-[3.1.0]-hexyl, bicyclo — 2.2.1]-hept-1-yl, norbornyl, spiro[4.5]decyl, spiro[4.4]nonyl, spiro[4.3]octyl, and spiro[4.2]heptyl.
  • An example of a tricycloalkyl group is adamantanyl.
  • Other cycloalkyl, bicycloalkyl, and tricycloalkyl groups are known in the art, and such groups are encompassed by the definitions "cycloalkyl", "bicycloalkyl” and "tricycloalkyl” herein.
  • Cycloalkenyl refers to non-aromatic carbocyclic cycloalkyl, bicycloalkyl, and tricycloalkyl moieties as defined above, except comprising one or more carbon-carbon double bonds connecting carbon ring members (an “endocyclic” double bond) and/or one or more carbon-carbon double bonds connecting a carbon ring member and an adjacent non-ring carbon (an “exocyclic” double bond).
  • cycloalkenyl groups include, but are not limited to, cyclopentenyl, cyclobutenyl, and cyclohexenyl, and a non-limiting example of a bicycloalkenyl group is norbomenyl.
  • Cycloalkyl, cycloalkenyl, bicycloalkyl, and bicycloalkenyl groups also include groups that are substituted with one or more oxo moieties. Examples of such groups with oxo moieties are oxocyclopentyl, oxocyclobutyl, oxocyclopentenyl, and norcamphoryl.
  • cycloalkenyl bicycloalkenyl, and tricycloalkenyl groups are known in the art, and such groups are included within the definitions "cycloalkenyl”, “bicycloalkenyl” and “tricycloalkenyl” herein.
  • aryl as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl, naphthyl, indenyl, indanyl, and fluorenyl. "Aryl” encompasses fused ring groups wherein at least one ring is aromatic.
  • heterocyclic refers to non-aromatic cyclic groups containing one or more heteroatoms, prefereably from one to four heteroatoms, each selected from O, S and N.
  • heterocycloalkyl groups are non-aromatic two-ringed cyclic groups, wherein said rings share one or two atoms, and wherein at least one of the rings contains a heteroatom (O, S, or N).
  • each ring in the heterobicycloalkyl contains up to four heteroatoms (i.e.
  • heterocyclic groups of this invention can also include ring systems substituted with one or more oxo moieties.
  • non-aromatic heterocyclic groups are aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, azepinyl, piperazinyl, 1 ,2,3,6-tetrahydropyridinyI, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholino, thiomorpholino, thioxanyl, pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1 ,3- dioxolanyl, pyrazolinyl, dihydro
  • Heteroaryl refers to aromatic groups containing one or more heteroatoms (O, S, or N), preferably from one to four heteroatoms.
  • a multicyclic group containing one or more heteroatoms wherein at least one ring of the group is aromatic is a "heteroaryl” group.
  • the heteroaryl groups of this invention can also include ring systems substituted with one or more oxo moieties.
  • heteroaryl groups are pyridinyl, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, quinolyl, isoquinolyl, 1 ,2,3,4- tetrahydroguinolyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, triazinyl, 1 ,2,4-trizainyl, 1,3,5-triazinyl, isoindolyl, 1-oxoisoindolyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl,
  • the foregoing groups may be C-attached or N-attached where such is possible.
  • a group derived from pyrrole may be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached).
  • the terms referring to the groups also encompass all possible tautomers.
  • Compounds of Formula l may have optical centers and therefore may occur in different enantiomeric, diastereomeric and meso configurations.
  • the invention includes all enantiomers, diastereomers, and other stereoisomers of such compounds of Formula I, as well as racemic and other mixtures thereof.
  • the invention also includes all tautomers of Formula I. When the compounds of Formula I of the present invention contain an optical center where R 3 and R 4 are attached, the "S" enantiomer is preferred.
  • the subject invention also includes isotopically-labeled compounds of Formula I, which are identical to those recited in Formula I, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number most abundant in nature.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, iodine, and chlorine, such as 3 H, 11 C, 14 C, 18 F, 123 1 and 125 l.
  • Isotopically- labeled compounds of Formula I for example those into which radioactive isotopes such as 3 H and 14 C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3 H, and carbon-14, i.e., 4 C, isotopes are particularly preferred for their ease of preparation and detectability.
  • Isotopically labeled compounds of Formula I of this invention can generally be prepared by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent in the preparation of said compounds.
  • Salts of compounds of Formula I can be obtained by forming salts with any acidic or basic group present on a compound of Formula I.
  • Examples of pharmaceutically acceptable salts of the compounds of Formula I are the salts of hydrochloric acid, p-toluenesulfonic acid, fumaric acid, citric acid, succinic acid, salicylic acid, oxalic acid, hydrobromic acid, phosphoric acid, methanesulfonic acid, tartaric acid, maleic acid, di-p-toluoyl tartaric acid, acetic acid, sulfuric acid, hydroiodic acid, mandelic acid, sodium, potassium, magnesium, calcium, and lithium.
  • Preferred embodiments of this invention include the following compounds of Formula I, all pharmaceutically acceptable salts thereof, complexes thereof, and derivatives thereof which convert into a pharmaceutically active compound upon administration:
  • the most preferred embodiments of this invention include the following compounds of Formula I, all pharmaceutically acceptable salts thereof, complexes thereof, and derivatives thereof which convert into a pharmaceutically active compound upon administration: 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-(5-furan-2-yl-2H-pyrazol-3-yl)- propionamide;
  • the present invention also provides a pharmaceutical composition for treating in a mammal a disease or condition associated with A ⁇ -peptide production, which pharmaceutical composition comprises a compound of Formula I in an amount effective in inhibiting gamma- secretase and a pharmaceutically acceptable carrier.
  • the present invention also provides a pharmaceutical composition for treating in a mammal, including in a human, a disease or condition associated with A ⁇ -peptide production, which pharmaceutical composition comprises a compound of Formula I in an amount effective in inhibiting A ⁇ -production and a pharmaceutically acceptable carrier.
  • the present invention also provides a pharmaceutical composition for treating in a mammal, including in a human, a disease or condition associated with A ⁇ -peptide production, which pharmaceutical composition comprises a compound of Formula I in an amount effective in inhibiting said disease or condition and a pharmaceutically acceptable carrier.
  • the present invention also provides a pharmaceutical composition for treating in a mammal, including in a human, a disease or condition selected from Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, cerebral amyloid angiopathy, systemic amyloidosis, a prion-mediated disease, inclusion body myositis, stroke, and Down's Syndrome, which pharmaceutical composition comprises a compound of Formula
  • the present invention also provides a pharmaceutical composition for treating in a mammal, including in a human, a disease or condition selected from Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis of the Dutch typecerebral amyloid angiopathy, systemic amyloidosis, a prion-mediated disease, inclusion body myositis, stroke, and Down's Syndrome, which pharmaceutical composition comprises a compound of Formula I in an amount effective in inhibiting said disease or condition and a pharmaceutically acceptable carrier.
  • a disease or condition selected from Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis of the Dutch typecerebral amyloid angiopathy, systemic amyloidosis, a prion-mediated disease, inclusion body myositis, stroke, and Down's Syndrome
  • the present invention also provides a method for treating in a mammal, including in a human, a disease or condition associated with A ⁇ -peptide production, which method comprises administering to said mammal an amount of a compound of Formula I effective in inhibiting A ⁇ -production.
  • the present invention also provides a method for treating in a mammal, including in a human, a disease or condition associated with A ⁇ -peptide production, which method comprises administering to said mammal an amount of a compound of Formula I effective in treating said disease or condition.
  • the present invention also provides a method for treating in a mammal, including in a human, a disease or condition selected from Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, cerebral amyloid angiopathy, systemic amyloidosis a prion-mediated disease, inclusion body myositis, stroke, and Down's Syndrome, which method comprises administering to said mammal an amount of a compound of Formula I effective in inhibiting A ⁇ -production.
  • a disease or condition selected from Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, cerebral amyloid angiopathy, systemic amyloidosis a prion-mediated disease, inclusion body myositis, stroke, and Down's Syndrome
  • the present invention also provides a method for treating in a mammal, including in a human, a disease or condition selected from Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, cerebral amyloid angiopathy, systemic amyloidosis, a prion-mediated disease, inclusion body myositis, stroke, and Down's Syndrome, which method comprises administering to said mammal an amount of a compound of Formula I effective in treating said disease or condition.
  • a disease or condition selected from Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, cerebral amyloid angiopathy, systemic amyloidosis, a prion-mediated disease, inclusion body myositis, stroke, and Down's Syndrome
  • Compounds in Formula I may be used alone or used as a combination with any other drug, including, but not limited to, any memory enhancement agent, antidepressant agent, anxiolytic, antipsychotic agent, sleep disorder agent, anti-inflammatory agent, anti-oxidant agent, cholesterol modulating agent (for example, an agent that lowers LDL or increases HDL),or anti-hypertension agent.
  • any memory enhancement agent including, but not limited to, any memory enhancement agent, antidepressant agent, anxiolytic, antipsychotic agent, sleep disorder agent, anti-inflammatory agent, anti-oxidant agent, cholesterol modulating agent (for example, an agent that lowers LDL or increases HDL),or anti-hypertension agent.
  • this invention also provides a pharmaceutical composition for treatment of a mammal, including a human, in need thereof comprising an effective amount of a compound of Formula I and an effective amount of another drug, for example a memory enhancement agent, antidepressant agent, anxiolytic, antipsychotic agent, sleep disorder agent, anti-inflammatory agent, anti-oxidant agent, cholesterol modulating agent (for example, an agent that lowers LDL or increases HDL),or anti- hypertension agent, and a pharmaceutically acceptable carrier.
  • a memory enhancement agent for example, antidepressant agent, anxiolytic, antipsychotic agent, sleep disorder agent, anti-inflammatory agent, anti-oxidant agent, cholesterol modulating agent (for example, an agent that lowers LDL or increases HDL),or anti- hypertension agent, and a pharmaceutically acceptable carrier.
  • This invention also provides a method for treating dementia, for example Alzheimer's disease, in a mammal, including in a human, comprising administering to the mammal an effective amount of a compound of Formula I and an effective amount of another drug, for example a memory enhancement agent, antidepressant agent, anxiolytic, antipsychotic agent, sleep disorder agent, anti- inflammatory agent, anti-oxidant agent, Cholesterol modulating agent (for example, an agent that lowers LDL or increases HDL), or anti-hypertension agent.
  • a memory enhancement agent for example, antidepressant agent, anxiolytic, antipsychotic agent, sleep disorder agent, anti- inflammatory agent, anti-oxidant agent, Cholesterol modulating agent (for example, an agent that lowers LDL or increases HDL), or anti-hypertension agent.
  • Compounds of Formula I, or any of the combinations described in the immediately preceding paragraph may optionally be used in conjunction with a know P-glycoprotein inhibitor, such as verapamil.
  • references herein to diseases and conditions "associated with A ⁇ -peptide production” mean a disease or condition that is caused at least in part by A ⁇ -peptide and/or the production thereof.
  • a ⁇ -peptide is a contributing factor, but not necessarily the only contributing factor, to "a disease or condition associated with A ⁇ -peptide production".
  • treatment refers to reversing, alleviating, or inhibiting the progress of a disorder or condition.
  • treatment and “treating” and like terms can also refer to decreasing the probability or incidence of occurrence of a disease or condition in a mammal compared to an untreated control population, or in the same mammal prior to treatment, according to the present invention.
  • Treatment or “treating” can also include delaying or preventing the onset of a disease or condition.
  • “Treatment” or “treating” as used herein also encompasses preventing the recurrence of disease or condition.
  • the pyrazole ring is always aromatic. To those skilled in the art it is well understood that the pyrazole ring is aromatic when R 8 is attached to either of the ring nitrogen atoms.
  • Scheme I refers to the preparation of compounds of the Formula I, la.
  • An aminopyrazole ⁇ (5-substituted - 2H - pyrazol-3-ylamine) or its corresponding tautomer (5- substituted - 2H - pyrazol-3-ylamine) is coupled with a nitrogen-protected aminoacid 2.
  • the nitrogen protecting group Y may be selected from any of the nitrogen protecting groups well known in the art, for example those described in literature such as Theodora W. Greene and Peter G. M. Wuts "Protective Groups in Organic Synthesis” Third Edition (1999).
  • Intermediate 1 may be prepared according to procedure shown in Scheme 111, using either a chlorovinylnitrile (Hartman, 1984, Synthesis, pp. 276-277) or a ketonitrile (Elnagdi, Tetrahedron. 1974, 31 , 63).
  • reagents can be used to couple 1 and 2 (wherein R is H) to form 3a or a mixture of 3a and 3 using standard peptide coupling methods known in art of organic chemistry (Scheme I).
  • HATU 1-(7- azabenzotriazole-1yl)-1 ,1 ,3,3,-tetramethyluronium hexafluorophosphate
  • PyBOP benzotriazole-l-yl)-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate
  • TBTU in DMF with a base, like HBTU/trialkylamine, or HBOt/EDC/trialkylamine in an appropriate solvent such as methylene chloride, THF, DMF or a mixture of two solvents, and mixture of reagents mixed to form a clear solution.
  • Fmoc Fluorenylmethylcarbonyl
  • HBTU 0-benzotriazoi-1-yl- ⁇ /, ⁇ /, ⁇ /', ⁇ /'-tetramethyluronium hexafluorophosphate
  • HATU 0-(7-azabenzotriazol-1-yl)- ⁇ /, ⁇ /, ⁇ /', ⁇ /'-tetramethyluronium hexafluorophosphate
  • CBZ-3 may be deprotected through catalytic hydrogenolysis in the presence of hydrogen (from about 1 to about 10 atmospheres), a heavy metal catalyst (e.g., palladium on carbon or palladium hydroxide on carbon, 1 to 10 percent catalyst loading, present at about 0.01 to about 0.50 times the of substrate), and a solvent (e.g., methanol, ethanol or ethyl acetate) at from about 20 to about 50 °C from about 1 to about 19 hours.
  • hydrogen from about 1 to about 10 atmospheres
  • a heavy metal catalyst e.g., palladium on carbon or palladium hydroxide on carbon, 1 to 10 percent catalyst loading, present at about 0.01 to about 0.50 times the of substrate
  • a solvent e.g., methanol, ethanol or ethyl acetate
  • intermediate 3 can be prepared by reacting 1_ and 2 (wherein R is alkyl, such as methyl or ethyl) in the presence of trialkylaluminum (such as AIMe 3 ) in an pprpriate solvent, such as THF/toluene or dichloroethane/toluene or toluene, at a suitable temperature, for example at a temperature of from about room temperature to about reflux, in an atmosphere or pressure reactor or sealed system.
  • R is alkyl, such as methyl or ethyl
  • trialkylaluminum such as AIMe 3
  • pprpriate solvent such as THF/toluene or dichloroethane/toluene or toluene
  • the compound ]a in Scheme I (or its corresponding 1 H-pyrazol tautomer) is prepared from the reaction of 4 with 9 where X is a leaving group (e.g., halide or triflate).
  • X is a leaving group (e.g., halide or triflate).
  • the reaction is carried out at about 0 to about 30°C in an organic solvent (e.g., methylene chloride, ethyl acetate, or DMF) in the presence of an organic base (e.g., triethylamine, diisopropylethylamine, or ⁇ /-methylmorpholine) from about 1 minute to about 24 hours.
  • an organic solvent e.g., methylene chloride, ethyl acetate, or DMF
  • an organic base e.g., triethylamine, diisopropylethylamine, or ⁇ /-methylmorpholine
  • the compound la in Scheme I is prepared from the reaction of 4 with 9 where X is -OH using a standard amide coupling agent (such as HBOt/EDC/triethylamine in methylene chloride or DMF) similar to that described above for the conversion of and 2 to 3a and/or 3.
  • a standard amide coupling agent such as HBOt/EDC/triethylamine in methylene chloride or DMF
  • the compound lb can be prepared according to the procedure of Scheme IV, employing the general conditions described for Scheme I.
  • R can be alkyl or benzyl.
  • the coupling of 9 and 11. in Scheme IV can be performed between about 0 and about 30°C in an organic solvent (e.g., methylene chloride, ethyl acetate, or DMF) in the presence of a base (e.g., triethylamine or diisopropylethylamine).
  • an organic solvent e.g., methylene chloride, ethyl acetate, or DMF
  • a base e.g., triethylamine or diisopropylethylamine
  • the above amide bond formation can be prepared from coupling of the ester (12 in Scheme IV) with 1 in the presence of trialkylaluminum (such as AIMe 3 ) in an appropriate solvent, eg., THF, toluene or a mixture of THF/toluene in an open or sealed tube at a temperature of between about 80 and about 150°C until complete conversion to the desired product (lb in Scheme IV).
  • trialkylaluminum such as AIMe 3
  • the ester group of R 7 can be converted to the corresponding amide using a similar method for amide bond formation, preferably using trimethylaluminum in an appropriate solvent or mixture of solvents, such as THF/toluene as shown in Scheme V.
  • the halo group X 2 can be generated according to Scheme VI by reacting the starting material wherein R 5 is H with NBS, NCS, l 2 in an appropriate solvents such as methylene chloride, or chloroform.
  • the halo group can be replaced with another group using the methods known in art, such as halogen-metal exchange, followed by quenching with an electrophile, or using typical Suzuki coupling conditions employing a catalyst such as palladium complex like tetrakis(triphenylphosphine)-palladium with sodium carbonate as a base in a suitable solvent such as THF, DME, Ethanol and a boronic acid.
  • a catalyst such as palladium complex like tetrakis(triphenylphosphine)-palladium with sodium carbonate as a base in a suitable solvent such as THF, DME, Ethanol and a boronic acid.
  • purification may be accomplished by crystallization or using chromatography on silica gel either with an ethyl acetate/hexane elution gradient or a chloroform/methanol elution gradient.
  • Pharmaceutically acceptable salts of a compound of formula I can be prepared in a conventional manner by treating a solution or suspension of the corresponding free base or acid with one chemical equivalent of a pharmaceutically acceptable acid or base. Conventional concentration or crystallization techniques can be employed to isolate the salts.
  • Suitable acids are acetic, lactic, succinic, maleic, tartaric, citric, gluconic, ascorbic, benzoic, cinnamic, fumaric, sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, sulfamic, sulfonic acids such as methanesulfonic, benzene sulfonic, p- toluenesulfonic, and related acids.
  • Illustrative bases are sodium, potassium, and calcium.
  • a compound of this invention may be administered alone or in combination with pharmaceutically acceptable carriers, in either single or multiple doses.
  • suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents.
  • the pharmaceutical compositions formed by combining a compound of formula I or a pharmaceutically acceptable salt thereof can then be readily administered in a variety of dosage forms such as tablets, powders, lozenges, syrups, injectable solutions and the like.
  • These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like.
  • tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch, methylcellulose, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tabletting purposes.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols.
  • the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and combinations thereof.
  • solutions containing a compound of this invention or a pharmaceutically acceptable salt thereof in sesame or peanut oil, aqueous propylene glycol, or in sterile aqueous solution may be employed.
  • aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
  • the sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
  • a compound of formula I or a pharmaceutically acceptable salt thereof can be administered orally, transdermally (e.g., through the use of a patch), parenterally (e.g. intravenously), rectally, or topically.
  • the daily dosage for treating a neurodegenerative disease or condition or a disease or condition associated with A ⁇ -peptide production will generally range from about 0.1 mg/kg to about 5 gm/kg body weight, preferably from about 0.1 mg/kg to about 100 mg/kg body weight. Variations based on the aforementioned dosage range may be made by a physician of ordinary skill taking into account known considerations such as the weight, age, and condition of the person being treated, the severity of the affliction, and the particular route of administration chosen.
  • a specific compound of formula I can be determined to inhibit A ⁇ -peptide production using biological assays known to those of ordinary skill in the art, for example the assays described below.
  • the activity of compounds of the invention in inhibiting gamma-secretase activity was determined in a solubilized membrane preparation generally according to the description provided in McLendon et al. Cell-free assays for ⁇ secretase activity, The FASEB Journal (Vol. 14, December 2000, pp. 2383-2386). Using such assay, compounds of the invention were determined to have an IC 0 activity for inhibiting gamma-secretase activity of less than about 32 micromolar.
  • Example 84 had an IC 50 of about 1 micromolar
  • Example 138 had an IC 50 of about 5 micromolar.
  • Step B Synthesis of 2-r2-(Difluoro-phenyl)-acetyl aminol-pentanoic acid methyl ester
  • Step C Conversion of 2-f2-(Difluoro-phenyl.-acetyl aminol-pentanoic acid methyl ester to 2-f2-(3.5-Difluoro-phenyl .-acetic acid
  • Step E Rearrangement of N-H-(5-Amino-3-phenyl-pyrazole-1-carbonyl)-butv ⁇ -2-(3,5- diflouro-phenvD-acetamide to 2-r2-(3,5-Difluoro-phenyl)-acetylaminel-pentanoic acid (5- phenyl-2H-pyrazole-3-yl, -amide
  • Step A Synthesis of ri-(5-Amino-3-phenyl-pyrazole-1-carbonyl)-butyll-carbamic acid tert-butyl ester
  • Step B Rearrangement/BOC Removal to give 2-Amino-1-(5-amino-3-phenyl- pyrazole-1-yl)-pentan-1-one Di-HCI Salt
  • Step C Synthesis of 2-f2-(3,5-Difluoro-phenyl)-acetylamino1-pentanoic acid (5- phenyl-2H-pyrazole-3-yl)-amide
  • Step A Coupling of BOC-Ala with Aminopyrazole to afford H -(5-Phenyl-2H-pyrazol- 3-ylcarbamoyl)-ethv ⁇ -carbamic acid tert-butyl ester:
  • Step B Deblocking of 1-(5-Phenyl-2H-pyrazol-3-ylcarbamoyl)-ethyl1-carbamic acid tert-butyl ester to Amino-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide Dihydrochloride
  • Step C Coupling of Benzylsulfonylchloride with amino-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide dihydrochloride to afford Phenylmethanesulfonylamino-N-(5-phenyl-2H-pyrazol- 3-yl)-propionamide

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides compounds of Formula (I): wherein R1,R2,R3, R4,R6,R7, R8 and A are as defined. Compounds of formula (I) have activity inhibiting production of Aβ-peptide. The invention also provides pharmaceutical compositions and methods for treating diseases, for example Alzheimer's disease, in mammals comprising compounds of Formula (I).

Description

PYRAZOLE COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS
Field of the Invention
The present invention relates to treatment of Alzheimer's disease and other neurodegenerative disorders in mammals, including in humans. This invention also relates to inhibiting in mammals, including in humans, the production of β-amyloid peptides (Aβ- peptides) which can contribute to formation of neurological deposits of amyloid protein. More particularly, this invention relates to pyrazole compounds useful for treatment of neurological disorders, such as Alzheimer's disease and Down's Syndrome, related to Aβ-peptide production. Background of the Invention
Dementia results from a wide variety of distinctive pathological processes. The most common pathological processes causing dementia are Alzheimer's disease (AD), cerebral amyloid angiopathy (CAA) and prion-mediated diseases (see, e.g., Haan et al. Clin. NeuroL Neurosurg. 1990, 92(4):305-310; Glenner et al. J Neurol. Sci. 1989, 94:1-28). AD affects nearly half of all people past the age of 85, the most rapidly growing portion of the United States population. As such, the number of AD patients in the United States is expected to increase from about 4 million to about 14 million by the middle of the next century.
Treatment of AD typically is the support provided by a family member in attendance. Stimulated memory exercises on a regular basis have been shown to slow, but not stop, memory loss. A few drugs, for example Aricept™, provide treatment of AD.
A hallmark of AD is the accumulation in the brain of extracellular insoluble deposits called amyloid plaques and abnormal lesions within neuronal cells called neurofibrillary tangles. Increased plaque formation is associated with an increased risk of AD. Indeed, the presence of amyloid plaques, together with neurofibrillary tangles, are the basis for definitive pathological diagnosis of AD.
The major components of amyloid plaques are the amyloid Aβ-peptides, also called Aβ-peptides, which consist of three proteins having 40, 42 or 43 amino acids, designated as the Aβ- o , Aβ^ , and Aβ^ peptides, respectively. The Aβ-peptides are thought to cause nerve cell destruction, in part, because they are toxic to neurons in vitro and in vivo. The Aβ peptides are derived from larger β-amyloid precursor proteins (APP proteins), which consist of four proteins containing 695, 714, 751 or 771 amino acids, designated as the APP695. APP7ι , APP75ι and APP771, respectively. Proteases are believed to produce the Aβ peptides by cleaving specific amino acid sequences within the various APP proteins. The proteases are named "secretases" because the Aβ-peptides they produce are secreted by cells into the extracellular environment. These secretases are each named according to the cleavage(s) they make to produce the Aβ-peptides. APP is cleaved by alpha- and beta- secretases, causing the release of soluble derivatives of protein (α-APPs and β-APPs) and the retention of membrane-bound 83- and 99-amino acid fragments (C83 and C99). These fragments are substrates for the enzyme gamma-secretase. Gamma-secretase produces the Aβ-peptide fragment from C99 and p3 from C83. Gamma-secretase and beta-secretase inhibitors are thus expected to inhibit the production of Aβ- peptide. (Haass, C. and Selkoe, D. J. 1993 CeJi 75:1039-1042; Selkoe, D. J. et. al. Annu. Rev. Cell Biol. 10, 373-403 (1994); Wolfe, M. S. et. al., Nature, 398, 513).
This invention relates to novel compounds that inhibit Aβ-peptide production, to pharmaceutical compositions comprising such compounds, and to methods of using such compounds to treat neuorodegenerative disorders. Summary of the Invention
The present invention provides compounds of Formula:
Figure imgf000003_0001
wherein:
A is selected from -C(=0)C(=0)- ,-C(=0)Z-, -C(=S)Z-, -C(=NR5)Z-, and -S(0)2-; wherein Z is -CH2-, -CH(OH)-, -CH(OC(=0)R11)-, -CH(NH2)-, -CH(CH2(OH))-,
-CH(CH(C C4 alkyl)(OH))-, or -CH(C(C C4 alkyl)(C C4 alkyl)(OH))-, for example
-CH(C(CH3)(CH3)(OH))- or -CH(C(CH3)(CH2CH3)(OH))-;
R1 is selected from C C20 alkyl and -C C20 alkoxy, C3-C8 cycloalkyl, (C4-
C8)cycloalkenyl, (Cs-C^bi- or tricycloalkyl, (C7-Cιι)bi- or tricycloalkenyl, (3-8 membered) heterocycloalkyl, (C6-C14)aryl, or (5-14 membered) heteroaryl, wherein said alkyl and alkoxy each optionally contains from one to five double or triple bonds, and wherein each hydrogen atom of said alkyl and alkoxy is optionally replaced with a fluorine; wherein when R1 is alkyl or alkoxy, R is optionally substituted with from one to three substituents R1a, and wherein when R1 is cycloalkyl, cycloalkenyl, bi- or tricycloalkyl, bi- or tricycloalkenyl, heterocycloalkyl, aryl, or heteroaryl, then R1 is optionally substituted with from one to three substituents R1b;
R1a is in each instance independently selected from -OH, -Ci-C, alkyl independently optionally containing from one to three double or triple bonds, -C-,-C6 alkoxy independently optionally containing from one to three double or triple bonds, -CI, -F, -Br, -I, -CN, -N02, -NR9R10, -C(=0)NR9R10, -S(0)nNR9R10, -C(=0)R11, -S(0)nR11, -C(=0)OR12, -C3-C8 cycloalkyl,
-C4-C8 cycloalkenyl, -(C5-Cιι)bi- or tricycloalkyl, -(Cr-C^bi- or tricycloalkenyl, -(3-8 membered) heterocycloalkyl, -(C6-C14)aryl, -(5-14 membered) heteroaryl, -(C6-C14) aryloxy, and -(5-14 membered) heteroaryloxy, wherein said alkyl, alkoxy, cycloalkyl, cycloalkenyl, bi- or tricycloalkyl, bi- or tricycloalkenyl, heterocycloalkyl, aryl, heteroaryl, aryloxy, and heteroaryloxy are each independently optionally substituted with from one to three R1b substituents;
R1 is in each instance independently selected from -CI, -F, -Br, -I, -CN, -N02, -(Czero- C4 alkylene)-NR9R10, -(Czer0-C4 alkylene)-C(=)ONR9R10, -(Czero-C4 alkylene)-C(=0)R11, -(Czero- C4 alkylene)-C(=0)OR12, -(Czero-C4 alkylene)-S(0)nR11, -(Czero-C4 alkylene)-S(0)nNR9R1°, - (Czero-C alkylene)-OH, -CτC6 alkyl independently optionally containing from one to three double or triple bonds,
Figure imgf000004_0001
alkoxy independently optionally containing from one to three double or triple bonds, -C C6 hydroxyalkyl, -(C6-C14) aryloxy, -(5-14 membered) heteroaryloxy, -(C6-C14) aryl, -(5-15 membered) heteroaryl, and -C C6 alkyl independently optionally containing from one to three double or triple bonds and independently substituted with from one to six atoms independently selected from F, CI, Br, and I;
R2 is selected from -H, -C C4 alkyl optionally containing one or two double or triple bonds, -C(=0)(CrC4 alkyl), -C6-C10 aryl, -SO2-(C6-C10 aryl), and -SO2-CH2-(C6-C10 aryl), and R2 is optionally substituted with from one to three substituents R1b;
R3 is selected from C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -(Czer0-C4 alkylene)- (C3-C6 cycloalkyl), and -(Czero-C4 alkylene)-(C3-C6 cycloalkenyl), wherein said alkyl, alkenyl and alkynyl are each optionally substituted with a substituent selected from -OH, C C alkoxy, and -S-(CrC4 alkyl); R4 is H, D, F, or C,-C4 alkyl; or R3 and ~R4 may together optionally form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, morpholino, piperidino, or perhydro-2H-pyran moiety, wherein said moiety formed by R3 and R4 is optionally substituted with one to three substituents independently selected from -OH, -CI, -F, -CN, -CF3, methyl, ethyl, methoxy, ethoxy, allyl, and -OCF3; R5 is selected from -H, -C C6 alkyl optionally substituted with from one to three R1a groups, and -C6-C10 aryl optionally substituted with from one to three R1a; or R5 and R1 may together optionally form a five to fourteen membered heteroaryl ring or a five to eight membered heterocycloalkyl ring, wherein said heteroaryl or heterocycloalkyl ring optionally contains one or two further heteroatoms selected from N, O, and S, and wherein said heterocycloalkyl ring optionally contains from one to three double bonds, and wherein said heteroaryl or heterocycloalkyl ring is optionally substituted from one to three substituents R1b groups;
R6 is selected from -H, -C C20 alkyl, -CI, -F, -Br, -I, -CN, -CF3, -C(=0)R11, -C(=0)OR12, -S(0)nNR9R1°, -S(0)nR11, -C(=NR9)R15, -(C3-C12) cycloalkyl, -(C4-C12) cycloalkenyl, and -C6-C10 aryl, wherein said alkyl, alkylene, cycloalkyl, cycloalkenyl, and aryl of R6 are each optionally substituted with from one to three R1b substituents; R7 is selected from H, -CI, -F, -Br, -I, -CN, -N02, -NR14R15, -CF3, -C(=0)NR14R15, -C(=0)R13, -S(O)nR13,-C(=0)0R13, -C(=NR9)R15, -S(0)nNR1 R15, -C1-C20 alkyl, -C C20 alkoxy, -(Czera-C4 alkylene)-(C3-C12 cycloalkyl), -(Czero-C4 alkylene)-((C4-C12)cycloalkenyl), -(CZero-C4 alkylene)-((C5-C20)bi- or tricycloalkyl), -(Czero-C4 alkyiene)-((C7-C20)bi- or tricycloalkenyl), -(Czsro-C4 alkylene)-((3-12 membered) heterocycloalkyl), -(Czero-C4 alkylene)- ((7-20 membered) heterobi- or heterotricycloalkyl), -(Czer0-C4 alkylene)-((C6-Cι )aryl), and -(Czera-C4 alkylene)-((5-15 membered) heteroaryl); wherein R7 is optionally substituted with from one to three substituents independently selected from R1a, -(CH2)1.10NR9R10, -C3-C|2 cycloalkyl, -((4-12 membered) heterocycloalkyl), -(C6-C14) aryl, -((5-15 membered) heteroaryl), -(4-12 membered) heterocycloalkoxy), -(C6-C12) aryloxy and -((5-12 membered) heteroaryloxy); said cycloalkyl, cycloalkenyl, bi- or tricycloalkyl, bi- or tricycloalkenyl, heterocycloalkyl, aryl, and heteroaryl of R7 are each optionally and independently substituted with from one to six F; said alkyl, alkoxy, and alkylene of R7 each optionally contains from one to five double or triple bonds; and each hydrogen atom of said alkyl, alkoxy, and alkylene of R7 is independently optionally replaced with a fluorine; or R6 and R7 or R7 and its proximate nitrogen atom may together optionally form a -(C6-C10) aryl ring, -(C6-C3) cycloalkyl or cycloalkenyl ring, a five to eight membered heterocycloalkyl or heterocycloalkenyl ring, a -(C10-C14) membered bicycloalkyl or bicycloalkenyl ring, or a ten to fourteen membered bicycloheteroalkyl or bicycloheteroalkenyl ring fused to the pyrazole ring of Formula I, wherein from one to three members of said heterocycloalkyl and heterocycloalkenyl rings, and from one to five members of said bicycloheteroalkyl and bicycloheteroalkenyl rings are selected independently from N, O and S, and wherein said aryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, bicycloalkyl, bicycloalkenyl, bicycloheteroalkyl, and bicycloheteroalkenyl rings optionally are substituted with from one to three R1b groups;
R8 is selected from -H, -CrC4 alkyl, -CI, -F, -Br, -I, -CN, -CF3, -C(=0)R11, -C(=0)OR12, and -C6-C 0aryl, with the proviso that the pyrazole ring is always aromatic and that R8 is attached to either ring nitrogen;
R9 and R10 are each independently selected from -H, -OH, -CpCe alkyl independently optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with a fluorine, -C C6 alkoxy independently optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with a fluorine, -C(=0)R11, -S(0)nR11, -C(=0)OR12, -S(0)nNR11R12, -(C_ero-C4 alky)ene)-(C3-C8 cycloalkyl), -(Czero-C4 alkylene)-(C4-C8 cycloalkenyl), -(Czero-C4 alkylene)-((C5-C11)bi- or tricycloalkyl), -(Czer0-C4 alkylene)-((C7-Cn)bi- or tricycloalkenyl), -(Czera-C4 alkylene)-(C6-C 4 aryl), -(Czero-C4 alkylene)-(3-8 membered heterocycloalkyl), and -(Czero-C4 alkylene)-(5-14 membered heteroaryl), wherein said cycloalkyl, cycloalkenyl, bi-or tricycloalkyl, bi- or tricycloalkenyl, aryl, heterocycloalkyl, and heteroaryl are each optionally independently substituted with from one to three substituents independently selected from -CI, -F, -Br, -I, -CN, -N02, -NR14R15, -C(=)ONR14R15, -C(=0)R11, -C(=0)OR12, -S(0)nR11, -S(0)nNR14R15, -OH, -C^C. alkyl independently optionally containing from one to three double or triple bonds, -Cι-C6 alkoxy independently optionally containing from one to three double or triple bonds, -CrC6 hydroxyalkyl, -(C6-C14) aryloxy, -(5-14 membered) heteroaryloxy, -(CZera-C )-((C6-C ) aryl), -(Czer0-C4)-(5-14 membered heteroaryl), and -C-i-Ce alkyl independently optionally containing from one to three double or triple bonds and independently substituted with from one to six atoms independently selected from F, CI, Br, and I; or NR9R10 can independently optionally form a heterocycloalkyl moiety of from four to seven ring members, said heterocycloalkyl moiety independently optionally comprising one or two further heteroatoms independently selected from N, O, and S, and independently optionally containing from one to three double bonds, and said heterocycloalkyl moiety independently optionally substituted with from one to three substituents independently selected from -CI, -F, -Br, -I, -CN, -N02, -NR14R15, -C(=)ONR14R15, -C(=0)R11, -C(=0)OR12, -S(0)nR11, -S(0)nNR14R15, -OH, -C C6 alkyl independently optionally containing from one to three double or triple bonds, -CrC6 alkoxy independently optionally containing from one to three double or triple bonds, -C C6 hydroxyalkyl independently optionally containing from one to three double or triple bonds, -(C6-C 4) aryloxy, -(5-14 membered) heteroaryloxy, -(Czero-C )-((C6-C1 ) aryl), -(Czera-C4)-(5-14 membered heteroaryl), and -C-ι-C6 alkyl independently optionally containing from one to three double or triple bonds and independently substituted with from one to six atoms independently selected from F, CI, Br, and I;
R11 and R12 are each independently selected from H, -C C6 alkyl, -(Czero-C4 alkylene)- (C3-C8 cycloalkyl), -(Czero-C4 alkylene)-(C4-C8 cycloalkenyl), -(Czero-C4 a!kylene)-((C5-C1 )bi- or tricycloalkyl), and -(Czer0-C4 alkylene)-((C -C11)bi- or tricycloalkenyl), -(Czera-C alkylene)-(C6- C10 aryl), -(Czero-C4 alkylene)-((3-8 membered) heterocycloalkyl), and -(Czero-C4 alkylene)-((5- 14 membered) heteroaryl), and R11 and R12 are independently optionally substituted with from one to three R1b; R13 is selected from H, -C C6 alkyl optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with a fluorine, -(Czero-C4 alkylene)-(C3-C 2 cycloalkyl), -(Czera-C alkylene)-(C4-Cι2 cycloalkenyl), -(Czero-C4 alkylene)-((C5-C20)bi- or tricycloalkyl), and -(Czero-C4 alkylene)-((C7-C20)bi- or tricycloalkenyl), -(Czero-C4 alkylene)-(C6-C14 aryl), -(Czera-C4 alkylene)-((3-12 membered) heterocycloalkyl), -(Czero-C4 alkylene)-((7-20 membered) heterobi- or heterotricycloalkyl), and -(Czero-C4 alkylene)- ((5-14 membered) heteroaryl), and R13 is optionally substituted with from one to three substituents R1b; R14 and R15 are each independently selected from -H, -C C2_ alkyl independently optionally containing from one to five double or triple bonds and wherein each hydrogen is independently optionally replaced with a fluorine, -C(=0)R11, -S(0)nR11, -C(=0)OR12, -S(0)nNR1 R12, -(Czero-C4 alkylene)-(C3-C12 cycloalkyl), -(Czero-C4 alkylene)-(C4-C12 cycloalkenyl), -(Czero-C alkylene)-((C5-C20)bi- or tricycloalkyl), -(Czero-C alkylene)-((C -C 0)bi- or tricycloalkenyl), -(Czero-C4 alkylene)-(C6-C14 aryl), -(Czero-C alkyiene)-(3-8 membered heterocycloalkyl), and -(Czera-C4 alkylene)-(5-14 membered heteroaryl), wherein said cycloalkyl, cycloalkenyl, bi-or tricycloalkyl, bi- or tricycloalkenyl, aryl, heterocycloalkyl, and heteroaryl are each independently optionally substituted with from one to three substituents independently selected from -C1-C6 alkyl independently optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with fluorine, -CI, -F, -Br, -I, -CN, -N02, -NH2, -OH, -C(=0)H, -S(0)nH, -C(=0)OH, -C(=0)NH2, -S(0)nNH2, -C C6 alkoxy independently optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with fluorine, -C-rC6 hydroxyalkyl independently optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with fluorine, -(5-14 membered) heteroaryloxy, -(C6-C14 aryloxy), -(Czero-C4 alkylene)-(C6-C1 aryl), -(Czero-C4 alkylene)-((5-14 membered) heteroaryl), and -CrC6 alkyl independently substituted with from one to six atoms independently selected from F, CI, Br, and I and independently optionally containing from one to three double or triple bonds; or NR1 R15 can independently optionally form a heterocycloalkyl moiety of from four to seven ring members, said heterocycloalkyl moiety independently optionally comprising one or two further heteroatoms independently selected from N, O, and S, and independently optionally containing from one to three double bonds, and said heterocycloalkyl moiety independently optionally substituted with from one to three substituents independently selected from -C C6 alkyl independently optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with fluorine, -CI, -F, -Br, -I, -CN, -N02, -NH2, -OH, -C(=0)H, -S(0)nH, -C(=0)OH, -C(=0)NH2, -S(0)nNH2, -d-C6 alkoxy independently optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with fluorine, -Cι-CB hydroxyalkyl independently optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with a fluorine, -(5-14 membered) heteroaryloxy, -(C6-C1 aryloxy), -(Czero-C4 alkylene)-(C6-C14 aryl), -(Czero-C4 alkylene)-((5-14 membered) heteroaryl), and -C C6 alkyl independently optionally containing from one to three double or triple bonds and independently substituted with from one to six atoms independently selected from F, CI, Br, and I; and n is in each instance an integer independently selected from zero, 1 , 2, and 3; and phamnaceutically-acceptable salts thereof.
Compounds of Formula I inhibit production of Aβ-peptide. Compounds of Formula I and their pharmaceutically acceptable salts are therefore useful in treating neurodegenerative disorders, for example AD, in mammals, including humans. In one embodiment, the present invention provides compounds of Formula I wherein
A is -C(=0)Z- or -C(=0)C(=0)-. If A is -C(=0)Z-, then Z is preferably -CH2- or -CH(OH)-.
In another embodiment, the invention provides compounds of Formula I wherein R3 is C C4 alkyl wherein each hydrogen is independently optionally replaced with a fluorine. In another embodiment R3 is allyl. In another embodiment R3 is methyl, ethyl, n-propyl, n-butyl, /-butyl, s-butyl, or -CH2CH2SCH3.
In another embodiment, the present invention provides compounds of Formula I wherein R6 is selected from hydrogen, methyl, ethyl, -F, -CI, -Br, and -CF3.
In another embodiment the present invention provides compounds of Formula I wherein R1 is -C2-Cι2 alkyl, C3-C8 cycloalkyl, (C5-C8)cycloalkenyl, -(d-C^bi- or tricycloalkyl, -(C7-Cn)bi- or tricycloalkenyl, (3-8 membered) heterocycloalkyl), -(C6-C10)aryl, -(5-10 membered) heteroaryl, or C C4 alkyl substituted with R a wherein R1a is -(C6-C10)aryl or -(5-
10 membered) heteroaryl.
In another embodiment, the present invention provides compounds of Formula I wherein R1 is C2-C10 alkyl, C3-C10 cycloalkyl, or -(CT-CnJbicycloalkyl, wherein said alkyl optionally contains from one to five double bonds, and wherein each hydrogen atom of said alkyl may optionally be replaced with a fluorine.
When R1 is C2-C 0 alkyl, in one embodiment, R1 is straight-chain. In another embodiment when R1 is C2-C10 alkyl, R1 is branched C3-C10 alkyl.
In another embodiment, R is C3-C10 alkyl comprising a tertiary carbon, for example /- propyl or 2-methylpropyl. In another embodiment, R1 is C4-C10 alkyl comprising a quaternary carbon, for example t-butyl.
In a further embodiment, R1 is selected from phenyl, thienyl, and pyridyl, optionally and independently substituted with one or two substituents R1b. When R1 is phenyl, thienyl, or pyridyl substituted optionally with one or two substituents R1b, then each R1b is preferably independently selected from -C C4 alkyl (in different embodiments, independently optionally containing one or two double or triple bonds), CF3, -C C4 alkoxy (in different embodiments, independently optionally containing one or two double or triple bonds), -F, -CI, -Br, phenyl, and phenoxy.
In a further embodiment, R1 is phenyl or pyridyl and is optionally substituted with one or two substituents R1b independently selected from -F, -CI and -CF3.
In another embodiment R1 is C3-C7 cycloalkyl, for example [2.2.1]-heptanyl. ln each of the aforementioned embodiments, A is preferably -C(=0)Z- or -C(=0)C(=0)-, Z preferably being -CH2- or -CH(OH)-. Furthermore, R3 is preferably C C4 alkyl, for example methyl, ethyl, /.-propyl, n-butyl, /-butyl, s-butyl, or R3 is allyl or -CH2CH2SCH3, and R6 is preferably hydrogen, methyl, ethyl, -F, -CI, -Br, and -CF3. In a further embodiment, A is -C(=0)Z- or -C(=0)C(=0)-; Z is -CH2- or -CH(OH)-; R3 is CrC alkyl wherein each hydrogen is independently optionally replaced with a fluorine, or R3 is allyl or -CH2CH2SCH3; R6 is selected from hydrogen, methyl, ethyl, -F, -CI, -Br, and -CF3; and R1 is -C2-C 2 alkyl, C3-C8 cycloalkyl, (C5-C8)cycloalkenyl, -(C5-Cn)bi- or tricycloalkyl, -(C7-Cn)bi- or tricycloalkenyl, -((3-8 membered) heterocycloalkyl), -(C6-C10)aryl, -(5-10 membered) heteroaryl, or C C4 alkyl substituted with R1a wherein R1a is -(C6-C 0)aryl or -(5-10 membered) heteroaryl.
In another embodiment, the present invention provides compounds of Formula I wherein A is -C(=0)Z- or -C(=0)C(=0)-; Z is -CH2- or -CH(OH)-; R3 is C C4 alkyl wherein each hydrogen is independently optionally replaced with a fluorine, or R3 is allyl or -CH2CH2SCH3; R6 is selected from hydrogen, methyl, ethyl, -F, -CI, -Br, and -CF3; and R1 is C2-C10 alkyl, C3-C10 cycloalkyl, or -(C7-C1 ^bicycloalkyl, wherein said alkyl optionally contains from one to five double bonds, and wherein each hydrogen atom of said alkyl is optionally replaced with a fluorine.
In another embodiment, the invention provides compounds of Formula I wherein A is -C(=0)Z- or -C(=0)C(=0)-; Z is -CH2- or -CH(OH)-; R3 is CrC4 alkyl wherein each hydrogen is independently optionally replaced with a fluorine, or R3 is allyl or -CH2CH2SCH3; R6 is selected from hydrogen, methyl, ethyl, -F, -CI, -Br, and -CF3; and R1 is straight chain C2-Cι0 alkyl or branched C3-C 0 alkyl.
In another embodiment, A is -C(=0)Z- or -C(=0)C(=0)-; Z is -CH2- or -CH(OH)-; R3 is C C4 alkyl wherein each hydrogen is independently optionally replaced with a fluorine, or R3 is allyl or -CH2CH2SCH3; R6 is selected from hydrogen, methyl, ethyl, -F, -CI, -Br, and -CF3; and R1 is C3-C10 alkyl comprising a tertiary carbon, for example /-propyl or 2- methylpropyl, or R1 is C4-C10 alkyl comprising a quaternary carbon, for example t-butyl.
In a further embodiment, A is -C(=0)Z- or -C(=0)C(=0)-; Z is -CH2- or -CH(OH)-; R3 is C1-C alkyl wherein each hydrogen is independently optionally replaced with a fluorine, or R3 is allyl or -CH2CH2SCH3; R6 is selected from hydrogen, methyl, ethyl, -F, -CI, -Br, and
-CF3; and R1 is selected from phenyl, thienyl, and pyridyl, optionally and independently substituted with one or two substituents R1b, preferably independently selected from -C-ι-C4 alkyl, CF3, -C1-C4 alkyoxy, -F, -CI, -Br, phenyl, and phenoxy. In a further embodiment, A is -C(=0)Z- or -C(=O)C(=0)-; Z is -CH2- or -CH(OH)-; R3 is Cι-C4 alkyl wherein each hydrogen is independently optionally replaced with a fluorine, or R3 is allyl or -CH2CH2SCH3; R6 is selected from hydrogen, methyl, ethyl, -F, -CI, -Br, and -CF3; and R1 is phenyl or pyridyl and is optionally substituted with one or two substituents R b independently selected from -F, -CI and -CF3.
In another embodiment, A is -C(=0)Z- or -C(=0)C(=0)-; Z is -CH2- or -CH(OH)-; R3 is C C alkyl wherein each hydrogen is independently optionally replaced with a fluorine, or R3 is allyl or -CH2CH2SCH3; R6 is selected from hydrogen, methyl, ethyl, -F, -CI, -Br, and -CF3; and R1 is C3-C7 cycloalkyl, for example [2.2.1]-heptanyl.
In another embodiment, this invention provides compounds of Formula I wherein R7 is selected from -H, -C C 2 alkyl optionally containing from one to five double bonds and wherein each hydrogen is independently optionally replaced with a fluorine, -CrC20 alkoxy optionally containing from one to five double bonds and wherein each hydrogen is independently optionally replaced with a fluorine, -F, -CI, -Br, -I, -CN, -N02, -(C3-C12) cycloalkyl optionally substituted with from one to six fluorine, -((3-12 membered) heterocycloalkyl) optionally substituted with from one to six fluorine, -(C6-C14) aryl, -((5-15 membered) heteroaryl), -CHO, -C(=0)(C1-C15 alkyl), -C(=0)((5-12 membered)heterocycloalkyl), -C(=0)(C6-C14 aryl), -C(=0)((5-15 membered) heteroaryl), - C(=0)(C5-C12 cycloalkyl), -C(=0)0(C C8 alkyl), -C(=O)N(C C10 alkylXd-do alkyl), - C(=O)N(C C10 alkyl)(C6-C10 aryl), -C(=O)NH(C6-C10 aryl), -C(=O)N(C1-C10 alkyl)((5-10
0 membered) heteroaryl), -C(=O)NH((5-10 membered) heteroaryl), -C(=O)N(C C10 alkyl)((5-10 membered) heterocycloalkyl), -C(=O)NH((5-10 membered) heterocycloalkyl), -C(=O)N(CrC 0 alkyl)(C5-C10 cycloalkyl), -C(=O)NH(C5-C10 cycloalkyl), -S oyd-ds alkyl), -S(0)n(C5-C12 cycloalkyl), -S(0)n(C6-C15 aryl), -S(O)n((5-10 membered) heteroaryl), wherein said alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each optionally substituted with from one to three substituents independently selected from -F, -CI, -Br, -I, -OH, -C C6 alkoxy independently optionally containing from one to three double or triple bonds, -NR9R10, -(CH^. ,oNR9R10, -C(=0)R11, -S(0)nR11, -C(=0)OR11, -C(=0)NR9R1°, -S(0)nNR9R10 -(C3-C12) cycloalkyl, -((4-12 membered) heterocycloalkyl), -(C6-C15) aryl, -((5-15 membered) heteroaryl), -((4-12 membered) heterocycloalkoxy), -(C6-C12) aryloxy and -((6-12 membered) heteroaryloxy).
In another embodiment, R7 is selected from -C C 2 alkyl optionally containing from one to five double bonds and wherein each hydrogen is independently optionally replaced with a fluorine, -(C3-C12) cycloalkyl optionally substituted with from one to six fluorine and -((3- 12 membered) heterocycloalkyl) optionally substituted with from one to six fluorine, wherein said alkyl, cycloalkyl and heterocycloalkyl are each optionally substituted with from one to three substitutents independently selected from -OH, -C C6 alkoxy independently optionally containing from one to three double or triple bonds, -NR9R10, -(CH2)1.6NR9R10, -C(=0)R11, -C(=0)OR11, -C(=0)NR9R10, -S(0)nNR9R10, -(C6-C14) aryl, -((5-15 membered) heteroaryl), - ((4-12 membered) heterocycloalkoxy), -(C6-C12) aryloxy and -((6-12 membered) heteroaryloxy).
In another embodiment, the invention provides compounds of Formula I wherein R7 is selected from -CrCι2 alkyl optionally containing from one to five double bonds, -(C3-C12) cycloalkyl and -((3-12 membered) heterocycloalkyl), wherein said alkyl, cycloalkyl and heterocycloalkyl are each optionally substituted with from one to three substitutents independently selected from -OH, -CrC6 alkoxy independently optionally containing from one to three double or triple bonds, -NR9R10, and -(CH2)1.6NR9R10.
In another embodiment, R7 is selected from -C C12 alkyl optionally containing from one to five double bonds, -(C3-C12) cycloalkyl and -(3-12 membered) heterocycloalkyl, wherein said alkyl, cycloalkyl and heterocycloalkyl are each optionally substituted with from one to three substitutents independently selected from -OH and -C C6 alkoxy independently optionally containing from one to three double or triple bonds.
In another embodiment, R7 is selected from -Cι-C12 alkyl optionally containing from one to five double bonds and -C3-C15 cycloalkyl, wherein said alkyl and cycloalkyl are each optionally independently substituted with from one to three substitutents -NR9R10.
In another embodiment, R7 is -((3-12 membered) heterocycloalkyl), wherein said heterocycloalkyl is optionally substituted with from one to three substitutents independently selected from -OH, -C C6 alkyl independently optionally containing from one to three double or triple bonds, -CrC6 alkoxy independently optionally containing from one to three double or triple bonds, -(C6-C10) aryl, and -(5-15 membered) heteroaryl.
The terms "halogen", "halo", and the like, as used herein, unless otherwise indicated, include F, CI, Br, and I.
The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight or branched moieties. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, and .-butyl.
The term "alkenyl", as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon double bond wherein alkyl is as defined above. Examples of alkenyl include, but are not limited to, ethenyl and propenyl. The term "alkynyl", as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon triple bond wherein alkyl is as defined above. Examples of alkynyl groups include, but are not limited to, ethynyl and 2-propynyl.
The term "cycloalkyl", as used herein, unless otherwise indicated, includes non- aromatic saturated cyclic alkyl moieties wherein alkyl is as defined above. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. "Bicycloalkyl" and "tricycloalkyl" groups are non-aromatic saturated carbocyclic groups consisting of two or three rings respectively, wherein said rings share at least one carbon atom. For purposes of the present invention, and unless otherwise indicated, bicycloalkyl groups include spiro groups and fused ring groups. Examples of bicycloalkyl groups include, but are not limited to, bicyclo-[3.1.0]-hexyl, bicyclo — 2.2.1]-hept-1-yl, norbornyl, spiro[4.5]decyl, spiro[4.4]nonyl, spiro[4.3]octyl, and spiro[4.2]heptyl. An example of a tricycloalkyl group is adamantanyl. Other cycloalkyl, bicycloalkyl, and tricycloalkyl groups are known in the art, and such groups are encompassed by the definitions "cycloalkyl", "bicycloalkyl" and "tricycloalkyl" herein. "Cycloalkenyl", "bicycloalkenyl", and "triccyloalkenyl" refer to non-aromatic carbocyclic cycloalkyl, bicycloalkyl, and tricycloalkyl moieties as defined above, except comprising one or more carbon-carbon double bonds connecting carbon ring members (an "endocyclic" double bond) and/or one or more carbon-carbon double bonds connecting a carbon ring member and an adjacent non-ring carbon (an "exocyclic" double bond). Examples of cycloalkenyl groups include, but are not limited to, cyclopentenyl, cyclobutenyl, and cyclohexenyl, and a non-limiting example of a bicycloalkenyl group is norbomenyl. Cycloalkyl, cycloalkenyl, bicycloalkyl, and bicycloalkenyl groups also include groups that are substituted with one or more oxo moieties. Examples of such groups with oxo moieties are oxocyclopentyl, oxocyclobutyl, oxocyclopentenyl, and norcamphoryl. Other cycloalkenyl, bicycloalkenyl, and tricycloalkenyl groups are known in the art, and such groups are included within the definitions "cycloalkenyl", "bicycloalkenyl" and "tricycloalkenyl" herein.
The term "aryl", as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl, naphthyl, indenyl, indanyl, and fluorenyl. "Aryl" encompasses fused ring groups wherein at least one ring is aromatic.
The terms "heterocyclic", "heterocycloalkyl", and like terms, as used herein, refer to non-aromatic cyclic groups containing one or more heteroatoms, prefereably from one to four heteroatoms, each selected from O, S and N. "Heterobicycloalkyl" groups are non-aromatic two-ringed cyclic groups, wherein said rings share one or two atoms, and wherein at least one of the rings contains a heteroatom (O, S, or N). Heterobicycloalkyl groups for purposes of the present invention, and unless otherwise indicated, include spiro groups and fused ring groups. In one embodiment, each ring in the heterobicycloalkyl contains up to four heteroatoms (i.e. from zero to four heteroatoms, provided that at least one ring contains at least one heteroatom). The heterocyclic groups of this invention can also include ring systems substituted with one or more oxo moieties. Examples of non-aromatic heterocyclic groups are aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, azepinyl, piperazinyl, 1 ,2,3,6-tetrahydropyridinyI, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholino, thiomorpholino, thioxanyl, pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1 ,3- dioxolanyl, pyrazolinyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, quinolizinyl, quinuclidinyl, 1 ,4-dioxaspiro[4.5]decyl, 1 ,4-dioxaspiro[4.4]nonyl, 1 ,4- dioxaspiro[4.3]octyl, and 1 ,4-dioxaspiro[4.2]heptyl.
"Heteroaryl", as used herein, refers to aromatic groups containing one or more heteroatoms (O, S, or N), preferably from one to four heteroatoms. A multicyclic group containing one or more heteroatoms wherein at least one ring of the group is aromatic is a "heteroaryl" group. The heteroaryl groups of this invention can also include ring systems substituted with one or more oxo moieties. Examples of heteroaryl groups are pyridinyl, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, quinolyl, isoquinolyl, 1 ,2,3,4- tetrahydroguinolyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, triazinyl, 1 ,2,4-trizainyl, 1,3,5-triazinyl, isoindolyl, 1-oxoisoindolyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzotriazolyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, dihydroquinolyl, tetrahydroquinolyl, dihydroisoquinolyl, tetrahydroisoquinolyl, benzofuryl, furopyridinyl, pyrolopyrimidinyl, and azaindolyl.
The foregoing groups, as derived from the compounds listed above, may be C-attached or N-attached where such is possible. For instance, a group derived from pyrrole may be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached). The terms referring to the groups also encompass all possible tautomers. Compounds of Formula l may have optical centers and therefore may occur in different enantiomeric, diastereomeric and meso configurations. The invention includes all enantiomers, diastereomers, and other stereoisomers of such compounds of Formula I, as well as racemic and other mixtures thereof. The invention also includes all tautomers of Formula I. When the compounds of Formula I of the present invention contain an optical center where R3 and R4 are attached, the "S" enantiomer is preferred.
The subject invention also includes isotopically-labeled compounds of Formula I, which are identical to those recited in Formula I, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number most abundant in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, iodine, and chlorine, such as 3H, 11C, 14C, 18F, 1231 and 125l. Compounds of Formula I of the present invention and pharmaceutically acceptable salts, complexes and derivatives of said compounds that contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Isotopically- labeled compounds of Formula I, for example those into which radioactive isotopes such as 3H and 14C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H, and carbon-14, i.e., 4C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labeled compounds of Formula I of this invention can generally be prepared by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent in the preparation of said compounds.
Salts of compounds of Formula I can be obtained by forming salts with any acidic or basic group present on a compound of Formula I. Examples of pharmaceutically acceptable salts of the compounds of Formula I are the salts of hydrochloric acid, p-toluenesulfonic acid, fumaric acid, citric acid, succinic acid, salicylic acid, oxalic acid, hydrobromic acid, phosphoric acid, methanesulfonic acid, tartaric acid, maleic acid, di-p-toluoyl tartaric acid, acetic acid, sulfuric acid, hydroiodic acid, mandelic acid, sodium, potassium, magnesium, calcium, and lithium.
Preferred embodiments of this invention include the following compounds of Formula I, all pharmaceutically acceptable salts thereof, complexes thereof, and derivatives thereof which convert into a pharmaceutically active compound upon administration:
2-(2-benzo[b]thiophen-4-yl-acetylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
N-(5-phenyl-2H-pyrazol-3-yl)-2-(2-thiophen-2-yl-acetylamino)-propionamide;
2-[2-(4-fluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide;
2-[2-(4-chloro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide;
N-(5-phenyl-2H-pyrazol-3-yl)-2-(2-m-tolyl-acetylamino)-propionamide;
2-[2-(2,5-difluoro-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide; 2-[2-hydroxy-2-(4-trifluoromethyl-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide;
2-(2-fluoro-2-phenyl-acetylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
N-(5-phenyl-2H-pyrazol-3-yl)-2-t2-(4-trifluoromethyl-phenyl)-acetylamino]- propionamide; 2-[2-(2-fluoro-5-trifluoromethyl-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide;
2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide;
N-(5-phenyl-2H-pyrazol-3-y|)-2-t2-(2-trifluoromethoxy-phenyl)-acetylamino]- propionamide;
2-[2-(3-phenoxy-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide; N-(5-phenyl-2H-pyrazol-3-yl)-2-[2-(4-trifluoromethoxy-phenyl)-acetylamino]- propionamide;
2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide; acetic acid (3,5-difluoro-phenyl)-[1-(5-pheny)-2H-pyrazol-3-ylcarbamoyl)- ethylcarbamoylj-methyl ester;
2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide;
2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide;
2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- butyramide;
2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- butyramide; N-(5-phenyl-2H-pyrazol-3-yl)-2-(2-pyridin-3-yl-acetylamino)-butyramide;
N-(5-phenyl-2H-pyrazol-3-yl)-2-(2-pyridin-2-yl-acetylamino)-butyramide;
2-[2-(5-bromo-pyridin-3-yl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
2-(3-cyclopentyl-propionylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
2-phenyl-cyclopropanecarboxylic acid [1 -(5-phenyl-2H-pyrazol-3-ylcarbamoyl)- propylj-amide;
N-[1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propyl]-succinamic acid methyl ester;
3,3-dimethyl-N-[1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propyl]-butyramide; dodecanoic acid [1 -(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propyl]-amide;
2-phenylacetylamino-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide; hexanoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propyl]-amide; heptanoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propyl]-amide;
2-(3-chloro-propionylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
2-(3-phenyl-propionylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
3-methyl-N-[1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propyl]-butyramide; decanoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propyl]-amide;
2-butyrylamino-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
5-chloro-pentanoic acid [1 -(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propyl]-amide;
2-[2-(3-phenoxy-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
3-{[1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propylcarbamoyl]-methyl}-piperidine-1- carboxylic acid tert-butyl ester;
N-(5-phenyl-2H-pyrazol-3-yl)-2-[2-(3-trifluoromethyl-phenyl)-acetylamino]-butyramide;
2-[2-(3-iodo-phenyl)-acetylam ino]-N-(5-phenyl-2 H-pyrazol-3-yl )-butyram ide; 2-[2-(3-chloro-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide; 4-methylsulfanyl-2-[2-(3-phenoxy-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- butyramide;
2-hydroxy-4-methyl-pentanoic acid [3-methylsulfanyl-1 -(5-phenyl-2H-pyrazol-3- ylcarbamoyl)-propyl]-amide;
2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-4-methylsulfanyl-N-(5-phenyl-2H- pyrazol-3-yl)-butyramide;
2-acetylamino-4-methylsulfanyl-N-(5-phenyl-2H-pyrazol-3-yl)- butyramide; 5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid ethyl ester;
5-[2-(2-hydroxy-4-methyl-pentanoylamino)-butyrylamino]-1H-pyrazole-3- carboxylic acid ethyl ester;
5-{2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-butyrylamino}-1 H-pyrazole-3- carboxylic acid ethyl ester; 2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-(5-hydroxymethyl-2H-pyrazol-3-yl)- butyramide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-(5-hydrazinocarbonyl-2H-pyrazol-3-yl)- butyramide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-[5-(5-phenyl-4H-[1 ,2,4]triazol-3-yl)-2H- pyrazol-3-yl]-butyramide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-(4-oxo-4,5-dihydro-pyrazolo[1,5- d][1,2,4]triazin-2-yl)-butyramide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-(4-methoxy-7-phenyl- pyrazolo[1 ,5-d][1 ,2,4]triazin-2-yl)-butyramide; 5-{2-t2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-
3-carboxylic acid amide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-(4-oxo-7-phenylsulfanylmethyl-4,5-dihydro- pyrazolo[1 ,5-d][1 ,2,4]triazin-2-yl)-butyramide;
5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid methylamide;
5-{2-t2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid (l-ethyl-propyl)-amide;
5-{2-t2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole- 3-carboxylic acid butyl-ethyl-amide; 5-{2-t2-(3,5-difluoro-phenyl)-acetylamino]-butyryiamino}-1 H-pyrazole-3-carboxylic acid cyclopropylmethyl-amide; 2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-[5-(morpholine-4-carbonyl)-2H-pyrazol-3-yl]- butyramide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-[5-(pyrrolidine-1-carbonyl)-2H-pyrazol-3-yl]- butyramide; 5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid piperidin-1-ylamide;
5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid sec-butyl-amide;
5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid ethyl-(2-hydroxy-ethyl)-amide;
5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid cyclohexyl-ethyl-amide;
5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid diallylamide; 2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-3-methyl-pentanoic acid (5-phenyl-2H-pyrazol- 3-yl)-amide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-3-methyl-pentanoic acid (5-butyl-2H-pyrazol-3- yl)-amide;
2-phenylacetylamino-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
2-[2-(3-fluoro-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
2-[2-(3,5-bis-trifluoromethyl-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide; 5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionylamino}-1 H-pyrazole-3-carboxylic acid butyl ester;
2-t2-(3,5-difluoro-phenyl)-acetylamino]-N-[5-(1 H-indol-3-yl)-2H-pyrazol-3-yl]- propionamide;
N-[5-(4-tert-butyl-phenyl)-2H-pyrazol-3-yl]-2-[2-(3,5-difluoro-phenyl)-acetylamino]- propionamide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-[5-(4-ethyl-phenyl)-2H-pyrazol-3-yl]- propionamide;
5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionylamino}-1 H-pyrazole-3-carboxylic acid ethyl ester; N-(4-bromo-5-phenyl-2H-pyrazol-3-yl)-2-[2-(3,5-difluoro-phenyl)-acetylamino]- propionamide; 1 -[2-(3,5-difluoro-phenyl)-acetylamino]-cyclopentanecarboxylic acid (5-phenyl-2H- pyrazo l-3-yl )-am ide;
N-(4-Chloro-5-phenyl-2H-pyrazol-3-yl)-2-[2-(3,5-difluoro-phenyl)-acetylamino]- propionamide; 2-[2-(3,5-difluoro-ρhenyl)-acetylamino]-pent-4-enoic acid (5-phenyl-2H-pyrazol-3-yl)- amide;
[(5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionylamino}-1 H-pyrazole-3-carbonyl)- aminoj-phenyl-acetic acid tert-butyl ester;
5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionylamino}-1H-pyrazole-3-carboxylic acid benzylamide;
2~[2-(3,5-difluoro-phenyl)-acetylamino]-pent-4-enoic acid (4-bromo-5-phenyl-2H- pyrazol-3-yl)-amide;
5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionylamino}-1 H- pyrazole-3-carboxylic acid methyl ester; 2-[2-(3,5-difluoro-phenyl)-acetylamino]-2-phenyl-N-(5-phenyl-2H-pyrazol-3-yl)- acetamide;
2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-pent-4-enoic acid (5-phenyl-2H- pyrazol-3-yl)-amide;
3-[2-(3,5-difluoro-ρhenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- succinamic acid methyl ester;
2-cyclohexyl-2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- acetamide;
2-cyclohexyl-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H- pyrazol-3-yl)-acetamide; 3-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H- pyrazol-3-yl)- succinamic acid benzyl ester;
2-(2-hydroxy-2-phenyl-acetylamino)-pent-4-enoic acid (5-thiophen-2-yl-2H-pyrazol-3- yl)-amide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-pentanoic acid (5-methyl-1-phenyl-1 H-pyrazol- 3-yl)-amide;
2-(2-bicyclo[2.2.1]hept-2-yl-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)- amide;
2-(2-cyclohexyl-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3- yl)-amide;
2-(3-hydroxy-2-phenyl-propionylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)- amide;
2-(2-adamantan-1-yl-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
4-methyl-pentanoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)- butylj-amide; 3-methyl-pentanoic acid [1 -(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide;
2-(2-cyclopentyl-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)- amide;
2-(2-cyclopropyl-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
2-(2-indan-2-yl-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide; 2-(3-phenyl-butyrylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
5-oxo-hexanoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide;
2-[2-(3-chloro-phenyl)-acetylamino]-pentanoic acid (5-phenyi-2H-pyrazol-3-yl)-amide;
2-[2-(3-bromo-phenyl)-acetylamino]-pentanoic acid (5-phenyl-2H-pyrazol-3-yI)-amide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-(5-furan-2-yl-2H-pyrazol-3-yl)-propionamide; N-(5-tert-butyl-2H-pyrazol-3-yl)-2-t2-(3,5-difluoro-phenyl)-acetylamino]-propionamide;
N-(5-cyclopropyl-2H-pyrazol-3-yl)-2-[2-(3,5-difluoro-phenyl)-acetylamino]- propionamide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-pentanoic acid (5-furan-2-yl-2H-pyrazol-3-yl)- amide; 2-[2-(3,5-difluoro-phenyl)-acetylamino]-pentanoic acid (5-thiophen-2~yl-2H-pyrazol-3- yl)-amide;
2-[2-(3,5-difluoro-phenyI)-acetylamino]-pentanoic acid (5-tert-butyl- 2H-pyrazol-3-yl)-amide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-pentanoic acid [5-(4-chloro-phenyl)-2H- pyrazol-3-yl]-amide;
N-(5-tert-butyl-2H-pyrazol-3-yl)-2-[2-(3,5-difluoro-phenyl)-acetylamino]-3-methyl- butyramide;
1-[2-(3,5-difluoro-phenyl)-acetylamino]- cyclopropanecarboxylic acid (5-tert-butyl-2H- pyrazol-3-yl)- amide; 1-[2-(3,5-difluoro-phenyl)-acetylamino]-cyclopropanecarboxylic acid (5-furan-2-yl-2H- pyrazol-3-yl)- amide;
N-(5-biphenyl-4-yl-2H-pyrazol-3-yl)-2-[2-(3,5-difluoro-phenyl)-acetylamino]- propionamide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-[5-(3',4'-dimethyl-biphenyl-4-yl)-2H-pyrazol- 3-yl]-propionamide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)- amide;
2-phenylmethanesulfonylamino-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
2-(4-fluoro-phenylmethanesulfonylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide; 2-(2-nitro-phenylmethanesulfonylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
2-phenylmethanesulfonylamino-pentanoic acid (5-tert-butyl-2H-pyrazol-3-yl)-amide;
2-(4-fluoro-phenylmethanesulfonylamino)-pentanoic acid (5-tert-butyl- 2H-pyrazol-3-yl)-amide;
N-(5-tert-butyl-2H-pyrazol-3-yl)-2-phenylmethanesulfonylamino-propionamide; 2-p-tolylmethanesulfonylamino-pentanoic acid (5-tert-butyl-2H-pyrazol-3-yl)-amide; 2-phenylmethanesulfonylamino-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide; 2-(decane-1-sulfonylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
2-(biphenyl-4-sulfonylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide; 2-(4-chloro-phenylmethanesulfonyIamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)- amide;
2-benzenesulfonylamino-4-methylsulfanyl-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide; 2-(4-fluoro-phenylmethanesulfonylamino)-pentanoic acid (5-phenyl-2H-ρyrazol-3-yl)- amide;
2-(4,5-dichloro-thiophene-2-sulfonylamino)-4-methylsulfanyl-N-(5-phenyl-2H-pyrazol- 3-yl)-butyramide; and
2-(4-chloro-phenylmethanesulfonylamino)-pentanoic acid (5-tert-butyl-2H-pyrazol-3- yl)-amide.
Other specific compounds of Formula I of the invention are: 2-t2-(3,5-difluoro-phenyl)-acetylamino]-N-[5-(5-methoxy-1 ,5-dimethyl-hexyl)-2H- pyrazol-3-yl]-butyramide;
2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-N-[5-(5-methoxy-1,5-dimethyl- hexyl)-2H-pyrazol-3-yl]-butyramide;
2-t2-(5-bromo-pyridin-3-yl)-2-hydroxy-acetylamino]-N-[5-(5-methoxy-1,5-dimethyl- hexyl)-2H-pyrazol-3-yl]-butyramide;
2-hydroxy-N-{1-[5-(5-methoxy-1 ,5-dimethyl-hexyl)-2H-pyrazol-3-ylcarbamoyl]-propyl}- 3-methyl-butyramide; 2-hydroxy-N-{1 -[5-(5-methoxy-1 ,5-dimethyl-hexyl)-2H-pyrazol-3-ylcarbamoyl]-propyl}-
3,3-dimethyl-butyramide;
2-(4,5-dichloro-thiophene-2-sulfonylamino)-4-methylsulfanyl-N-(5-phenyl-2H-pyrazol- 3-yl)-butyramide;
2-(4-chloro-phenylmethanesulfonylamino)-pentanoic acid (5-tert-butyl-2H-pyrazol-3- yl)-amide; and pharmaceutically acceptable salts thereof, complexes thereof, and derivatives thereof which convert into a pharmaceutically active compound upon administration. Other preferred compounds of Formula I are:
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid benzyl-methyl-amide;
3,7-Dimethyl-oct-6-enoic acid [1 -(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide; 2-[2-(1-Benzyl-piperidin-3-yl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide; 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid dibutylamide;
3-{[1-(5-Phenyl-2H-pyrazol-3-ylcarbamoyl)-propylcarbamoyl]-methyl}-piperidine-1- carboxylic acid tert-butyl ester; 3-{[1 -(5-Phenyl-2H-pyrazol-3-ylcarbamoyl)-propylcarbamoyl]-methyl}-piperidine-1 - carboxylic acid tert-butyl ester;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid ethyl-methyl-amide;
2-[2-(3-Chloro-phenyl)-acetylamino]-pentanoic acid [5-(4-chloro-phenyl)-2H-pyrazol- 3-yl]-amide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-[5-(4-phenyl-piperazine-1-carbonyl)-2H- pyrazol-3-yl]-butyramide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-[5-(2-hydroxymethyl-pyrrolidine-1- carbonyl)-2H-pyrazol-3-yl]-butyramide; 2-(2-Cyclohexyl-2-hydroxy-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)- amide;
2-(2-Cyclohexyl-2-hydroxy-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)- amide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-[5-(2,6-dimethyl-morpholine-4-carbonyl)- 2H-pyrazol-3-yl]-butyramide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid (2-hydroxy-ethyl)-propyl-amide;
1-(5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carbonyl)- piperidine-3-carboxylic acid ethyl ester; 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid (2,2-dimethoxy-ethyl)-methyl-amide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid diethylamide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid diisobutylamide;
3,7-Dimethyl-oct-6-enoic acid [1-(5-phenyl-2H-pyrazol-3-yIcarbamoyl)-butyl]-amide;
3,7-Dimethyl-oct-6-enoic acid [1 -(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid dibenzylamide; 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-[5-(2-ethyl-piperidine-1-carbonyl)-2H- pyrazol-3-yi]-butyramide; 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid benzyl-ethyl-amide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid butyl-methyl-amide; 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid dihexylamide;
2-[2-(2,3-Difluoro-phenyl)-2-hydroxy-acetylamino]-pentanoic acid (5-phenyl-2H- pyrazol-3-yl)-amide;
2-[2-(1-Benzenesulfonyl-piperidin-3-yl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3~yl)- butyramide;
2-[2-(1-Acetyl-piperidin-3-yl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid dipropylamide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-[5-(1-methyl-1 H-benzoimidazol-2-yl)-2H- pyrazol-3-yl]-butyramide;
2-[2-(5-Bromo-pyridin-3-yl)-acetylamino]-pentanoic acid [5-(4-chloro-phenyl)-2H- pyrazol-3-yl]-amide;
2-[2-(3-Trifluoromethyl-phenyl)-acetylamino]-pentanoic acid [5-(4-chloro-phenyl)-2H- pyrazol-3-yl]-am id e; 2-[2-(3-Methoxy-phenyi)-acetylamino]-pentanoic acid [5-(4-chloro-phenyl)-2H-pyrazol-
3-yl]-amide;
3-{1-[5-(4-Chloro-phenyl)-2H-pyrazol-3-ylcarbamoyl]-butylcarbamoyl}-5-methyl-2- propyl-hexanoic acid tert-butyl ester;
N-(5-Phenyl-2H-pyrazol-3-yl)-2-[2-(5-phenyl-pyridin-3-yl)-acetylamino]-butyramide; E-224354: N-(5-Phenyl-2H-pyrazol-3-yl)-2-(2-piperidin-1-yl-acetyIamino)-butyramide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid dipentylamide;
2-Hydroxy-hexanoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide;
2-[2-(2-Chloro-phenyl)-2-hydroxy-acetylamino]-pentanoic acid (5-phenyl-2H-pyrazol- 3-yl)-amide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoic acid (2H-pyrazol-3-yl)-amide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-[5-(5,6,7,8-tetrahydro- [1 ,2,4]triazolo[4,3- a]pyridin-3-yl)-2H-pyrazol-3-yl]-butyramide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-3,3-dimethyl-N-(5-phenyl-2H-pyrazol-3-yl)- butyramide;
2-(2-Hydroxy-3-methyl-butyrylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)- amide; 2-[2-(5-o-Tolyl-pyridin-3-yl)-acetylamino]-pentanoic acid [5-(4-chloro-phenyl)-2H- pyrazol-3-yl]-amide;
2-Hydroxy-3-methyl-N-[1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propyl]-butyramide;
2-[2-(2-Oxo-azepan-3-yl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide; 2-[2-(2-Oxo-azepan-3-yl)-acetylamino]-N-(5-phenyI-2H-pyrazol-3-yl)-butyramide;
3,7-Dimethyl-octa-2,6-dienoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]- amide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoic acid (5-methyl-2H-pyrazol-3-yl)- amide; and 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-hexanoic acid (5-phenyl-2H-pyrazol-3-yl)- amide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-(4-oxo-4,5-dihydro-pyrazolo[1 ,5- d][1 ,2,4]tria2in-2-yl)-butyramide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-(4-methoxy-7-phenyl-pyrazolo[1 ,5- d][1 ,2,4]triazin-2-yl)-butyramide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-(4-oxo-7-phenylsulfanylmethyl-4,5-dihydro- pyrazolo[1 ,5-d][1 ,2,4]triazin-2-yl)-butyramide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoic acid (5-methyl-1 -phenyl-1 H- pyrazol-3-yl)-amide; and pharmaceutically acceptable salts thereof, complexes thereof, and derivatives thereof which convert into a pharmaceutically active compound upon administration.
The most preferred embodiments of this invention include the following compounds of Formula I, all pharmaceutically acceptable salts thereof, complexes thereof, and derivatives thereof which convert into a pharmaceutically active compound upon administration: 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-(5-furan-2-yl-2H-pyrazol-3-yl)- propionamide;
N-(5-tert-Butyl-2H-pyrazol-3-yl)-2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionamide;
N-(5-Cyclopropyl-2H-pyrazol-3-yl)-2-[2-(3,5-difluoro-phenyl)-acetylamino]- propionamide; 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)- amide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoic acid (5-pfιenyl-2H-pyrazol-3-yl)- amide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoic acid (5-furan-2-yl-2H-pyrazol-3-yl)- amide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoic acid (5-thiophen-2-yl-2H-pyrazol-3- yl)-amide; 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoic acid (5-cyclopropyl-2H-pyrazol-3- yl)-amide;
2-[2-(3,5-Difiuoro-phenyl)-acetylamino]-pentanoic acid [5-(4-chloro-phenyl)-2H- pyrazol-3-yl]-am ide; 2-Phenylacetylamino-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
2-[2-(3-Fluoro-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide;
2-[2-(4-Fluoro-3-trifluoromethyl-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide;
2-[2-(3-Phenoxy-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pent-4-enoic acid (5-phenyl-2H-pyrazol-3-yl)- amide;
2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-4-methylsulfanyl-N- (5-phenyl-2H- pyrazol-3-yl)-butyramide;
2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- butyramide;
2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- butyramide; 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid ethyl ester;
5-[2-(2-Hydroxy-4-methyl-pentanoylamino)-butyrylamino]-1 H-pyrazole-3-carboxylic acid ethyl ester;
5-{2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-butyrylamino}-1 H-pyrazole-3- carboxylic acid ethyl ester;
2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide;
N-(5-Phenyl-2H-pyrazol-3-yl)-2-(2-pyridin-3-yl-acetylamino)-butyramide;
2-[2-(5-Bromo-pyridin-3-yl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide; 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid butyl-ethyl-amide;
2-[2-(3-Phenoxy-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid piperidin-1-ylamide; 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid cyclohexyl-ethyl-amide;
2-(2-Cyclohexyl-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide; 4-Methyl-pentanoic acid [1 -(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide;
3-Methyl-pentanoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide;
2-(2-Cyclopentyl-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
2-(2-Cyclopropyl-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide; 2-[2-(3-Chloro-phenyl)-acetylamino]-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
2-[2-(3-Bromo-phenyl)-acetylamino]-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid benzyl-methyl-amide;
3,7-Dimethyl-oct-6-enoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide; 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid dibutylamide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid ethyl-methyl-amide;
2-(2-Cyclohexyl-2-hydroxy-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)- amide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-[5-(2,6-dimethyl-morpholine-4-carbonyl)- 2H-pyrazol-3-yl]-butyram ide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid (2-hydroxy-ethyl)-propyl-amide; 1 -(5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carbonyl)- piperidine-3-carboxylic acid ethyl ester;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid (2,2-dimethoxy-ethyl)-methyl-amide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid diisobutylamide;
3,7-Dimethyl-oct-6-enoic acid [1 -(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid dibenzylamide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-[5-(2-ethyl-piperidine-1-carbonyl)-2H- pyrazol-3-yl]-butyramide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid benzyl-ethyl-amide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid butyl-methyl-amide; 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid dihexylamide; 2-[2-(2,3-Difluoro-phenyl)-2-hydroxy-acetylamino]-pentanoic acid (5-phenyl-2H- pyrazol-3-yl)-amide;
2-[2-(1-Acetyl-piperidin-3-yl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid dipropylamide;
N-(5-Phenyl-2H-pyrazol-3-yl)-2-t2-(5-phenyl-pyridin-3-yl)-acetylamino]-butyramide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid dipentylamide;
2-[2-(5-o-Tolyl-pyridin-3-yl)-acetylamino]-pentanoic acid [5-(4-chloro-phenyl)-2H- pyrazol-3-yl]-amide; and
2-Hydroxy-3-methyl-N-[1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-ethyl]-butyramide.
The present invention also provides a pharmaceutical composition for treating in a mammal a disease or condition associated with Aβ-peptide production, which pharmaceutical composition comprises a compound of Formula I in an amount effective in inhibiting gamma- secretase and a pharmaceutically acceptable carrier.
The present invention also provides a pharmaceutical composition for treating in a mammal, including in a human, a disease or condition associated with Aβ-peptide production, which pharmaceutical composition comprises a compound of Formula I in an amount effective in inhibiting Aβ-production and a pharmaceutically acceptable carrier. The present invention also provides a pharmaceutical composition for treating in a mammal, including in a human, a disease or condition associated with Aβ-peptide production, which pharmaceutical composition comprises a compound of Formula I in an amount effective in inhibiting said disease or condition and a pharmaceutically acceptable carrier.
The present invention also provides a pharmaceutical composition for treating in a mammal, including in a human, a disease or condition selected from Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, cerebral amyloid angiopathy, systemic amyloidosis, a prion-mediated disease, inclusion body myositis, stroke, and Down's Syndrome, which pharmaceutical composition comprises a compound of Formula
I in an amount effective in inhibiting Aβ-production and a pharmaceutically acceptable carrier. The present invention also provides a pharmaceutical composition for treating in a mammal, including in a human, a disease or condition selected from Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis of the Dutch typecerebral amyloid angiopathy, systemic amyloidosis, a prion-mediated disease, inclusion body myositis, stroke, and Down's Syndrome, which pharmaceutical composition comprises a compound of Formula I in an amount effective in inhibiting said disease or condition and a pharmaceutically acceptable carrier.
The present invention also provides a method for treating in a mammal, including in a human, a disease or condition associated with Aβ-peptide production, which method comprises administering to said mammal an amount of a compound of Formula I effective in inhibiting Aβ-production.
The present invention also provides a method for treating in a mammal, including in a human, a disease or condition associated with Aβ-peptide production, which method comprises administering to said mammal an amount of a compound of Formula I effective in treating said disease or condition.
The present invention also provides a method for treating in a mammal, including in a human, a disease or condition selected from Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, cerebral amyloid angiopathy, systemic amyloidosis a prion-mediated disease, inclusion body myositis, stroke, and Down's Syndrome, which method comprises administering to said mammal an amount of a compound of Formula I effective in inhibiting Aβ-production.
The present invention also provides a method for treating in a mammal, including in a human, a disease or condition selected from Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, cerebral amyloid angiopathy, systemic amyloidosis, a prion-mediated disease, inclusion body myositis, stroke, and Down's Syndrome, which method comprises administering to said mammal an amount of a compound of Formula I effective in treating said disease or condition. Compounds in Formula I may be used alone or used as a combination with any other drug, including, but not limited to, any memory enhancement agent, antidepressant agent, anxiolytic, antipsychotic agent, sleep disorder agent, anti-inflammatory agent, anti-oxidant agent, cholesterol modulating agent (for example, an agent that lowers LDL or increases HDL),or anti-hypertension agent. Accordingly, this invention also provides a pharmaceutical composition for treatment of a mammal, including a human, in need thereof comprising an effective amount of a compound of Formula I and an effective amount of another drug, for example a memory enhancement agent, antidepressant agent, anxiolytic, antipsychotic agent, sleep disorder agent, anti-inflammatory agent, anti-oxidant agent, cholesterol modulating agent (for example, an agent that lowers LDL or increases HDL),or anti- hypertension agent, and a pharmaceutically acceptable carrier. This invention also provides a method for treating dementia, for example Alzheimer's disease, in a mammal, including in a human, comprising administering to the mammal an effective amount of a compound of Formula I and an effective amount of another drug, for example a memory enhancement agent, antidepressant agent, anxiolytic, antipsychotic agent, sleep disorder agent, anti- inflammatory agent, anti-oxidant agent, Cholesterol modulating agent (for example, an agent that lowers LDL or increases HDL), or anti-hypertension agent. Compounds of Formula I, or any of the combinations described in the immediately preceding paragraph, may optionally be used in conjunction with a know P-glycoprotein inhibitor, such as verapamil.
References herein to diseases and conditions "associated with Aβ-peptide production" mean a disease or condition that is caused at least in part by Aβ-peptide and/or the production thereof. Thus, Aβ-peptide is a contributing factor, but not necessarily the only contributing factor, to "a disease or condition associated with Aβ-peptide production".
The terms "treatment", "treating", and the like, refer to reversing, alleviating, or inhibiting the progress of a disorder or condition. As used herein, "treatment" and "treating" and like terms can also refer to decreasing the probability or incidence of occurrence of a disease or condition in a mammal compared to an untreated control population, or in the same mammal prior to treatment, according to the present invention. "Treatment" or "treating" can also include delaying or preventing the onset of a disease or condition. "Treatment" or "treating" as used herein also encompasses preventing the recurrence of disease or condition.
In the present invention the pyrazole ring is always aromatic. To those skilled in the art it is well understood that the pyrazole ring is aromatic when R8 is attached to either of the ring nitrogen atoms.
It is also well known that when R8 is hydrogen, two tautomeric forms of formula l exist in solution equilibrium.
Detailed Description of the Invention Compounds of Formula I may be prepared according to the following reaction Schemes and discussion. Unless otherwise indicated, R1, R2, R3, R4, R5, R6, R7, R8 and A in the reaction schemes and discussion that follows are as defined above.
Figure imgf000029_0001
Scheme I refers to the preparation of compounds of the Formula I, la. An aminopyrazole Λ (5-substituted - 2H - pyrazol-3-ylamine) or its corresponding tautomer (5- substituted - 2H - pyrazol-3-ylamine) is coupled with a nitrogen-protected aminoacid 2. The nitrogen protecting group Y may be selected from any of the nitrogen protecting groups well known in the art, for example those described in literature such as Theodora W. Greene and Peter G. M. Wuts "Protective Groups in Organic Synthesis" Third Edition (1999). Examples of a protected nitrogen group for the reactant 2 include where -C(=0)OY in 2 is butoxycarbonyl ("BOC", Y = tert-butyl) or benzyloxycarbonyl ("CBZ", Y = benzyl), which are prepared with either di-tert-butyl dicarbonate (Aldrich Chemical Company, Milwaukee Wisconsin), or benzyl chloroformate (Aldrich) in the presence of either an inorganic or organic base (e.g., sodium carbonate or triethylamine) at about 0 to about 30 °C in an organic solvent (e.g., methylene chloride) or in a mixture of water and an organic solvent (e.g., ethyl acetate) (Scheme II) (see, Muller, Methoden Der Orαanischen Chemie. "Vierte Auglage - Synthesis von Peptiden I" - Houben Weyl - Georg-Thieme Verlag Stuttgart, 1974, Band XV/1). Scheme II
Figure imgf000030_0001
Intermediate 1 may be prepared according to procedure shown in Scheme 111, using either a chlorovinylnitrile (Hartman, 1984, Synthesis, pp. 276-277) or a ketonitrile (Elnagdi, Tetrahedron. 1974, 31 , 63).
Scheme III
Figure imgf000030_0002
Numerous reagents, well-known in the art, can be used to couple 1 and 2 (wherein R is H) to form 3a or a mixture of 3a and 3 using standard peptide coupling methods known in art of organic chemistry (Scheme I). Activation of the carboxylic acid with HATU (0-(7- azabenzotriazole-1yl)-1 ,1 ,3,3,-tetramethyluronium hexafluorophosphate) or PyBOP (benzotriazole-l-yl)-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate) or TBTU in DMF with a base, like HBTU/trialkylamine, or HBOt/EDC/trialkylamine in an appropriate solvent such as methylene chloride, THF, DMF or a mixture of two solvents, and mixture of reagents mixed to form a clear solution. Many of these peptide coupling agents or resins for solid phase synthesis such as Fmoc (Fluorenylmethylcarbonyl)-protected hydroxylamine bound to polystylene beads is common and well known in literature. Deprotection of the Fmoc group can be accomplished under standard conditions using 20% piperidine in DMF. References :0-benzotriazoi-1-yl-Λ/,Λ/,Λ/',Λ/'-tetramethyluronium hexafluorophosphate ("HBTU", Aldrich Chemical Company) and 0-(7-azabenzotriazol-1-yl)-Λ/,Λ/,Λ/',Λ/'-tetramethyluronium hexafluorophosphate ("HATU", Aldrich) (See, Fieser, Reagents for Organic Synthesis, 1986, Wiley Interscience, New York, Vol. 12, p. 44; Hruby, Biorganic Chemistry: Peptides and Proteins, 1998, Oxford University press, New York, pp. 27-64; Muller, Methoden Der Organischen Chemie, Vierte Auflage - Synthese von Peptiden II - Houben Weyl, George- Thieme Verlag Stuttgart, 1974, Band XV/2). When optically active reagents are employed, reaction conditions, such as temperature, time and the selection of the base, must be carefully controlled to avoid racemization. The protected amino group or carboxylic acid group can be prepared by methods well known in the literature for amino acid protecting groups as described in Organic chemistry Journal, textbook such as "Protective Groups in Organic Syntehsis" by T. W. Greene and Wuts as described above. Compound 3a can be heated at an appropriate temperature from about 80 to about 180°C, preferably at about 150 to about 170°C to provide compound 3. Intermediate 3 of Scheme I, is deprotected to afford aminoamide 4 (or its corresponding 1/-/-pyrazol tautomer) either through treatment with strong acid in the case of butoxycarbonyl or through hydrogenolysis in the case of carbobenzyloxycarbonyl. Specifically, BOC-3, on treatment with hydrochloric acid or trifluoroacetic acid in an organic solvent (e.g., dioxane, THF, or methylene chloride), at about 30 °C for about 1 to about 19 hours affords the corresponding salts of 4. Alternatively, CBZ-3 may be deprotected through catalytic hydrogenolysis in the presence of hydrogen (from about 1 to about 10 atmospheres), a heavy metal catalyst (e.g., palladium on carbon or palladium hydroxide on carbon, 1 to 10 percent catalyst loading, present at about 0.01 to about 0.50 times the of substrate), and a solvent (e.g., methanol, ethanol or ethyl acetate) at from about 20 to about 50 °C from about 1 to about 19 hours.
Alternatively, intermediate 3 can be prepared by reacting 1_ and 2 (wherein R is alkyl, such as methyl or ethyl) in the presence of trialkylaluminum (such as AIMe3) in an pprpriate solvent, such as THF/toluene or dichloroethane/toluene or toluene, at a suitable temperature, for example at a temperature of from about room temperature to about reflux, in an atmosphere or pressure reactor or sealed system.
The compound ]a in Scheme I (or its corresponding 1 H-pyrazol tautomer) is prepared from the reaction of 4 with 9 where X is a leaving group (e.g., halide or triflate). The reaction is carried out at about 0 to about 30°C in an organic solvent (e.g., methylene chloride, ethyl acetate, or DMF) in the presence of an organic base (e.g., triethylamine, diisopropylethylamine, or Λ/-methylmorpholine) from about 1 minute to about 24 hours. Alternatively, the compound la in Scheme I is prepared from the reaction of 4 with 9 where X is -OH using a standard amide coupling agent (such as HBOt/EDC/triethylamine in methylene chloride or DMF) similar to that described above for the conversion of and 2 to 3a and/or 3.
Alternatively, the compound lb can be prepared according to the procedure of Scheme IV, employing the general conditions described for Scheme I. In Scheme IV, R can be alkyl or benzyl. The coupling of 9 and 11. in Scheme IV can be performed between about 0 and about 30°C in an organic solvent (e.g., methylene chloride, ethyl acetate, or DMF) in the presence of a base (e.g., triethylamine or diisopropylethylamine). When R is alkyl, either acidic or basic hydrolysis may be used to convert 12 to 13. If R is benzyl, catalytic hydrogenolysis may also be used to prepare 13.
Scheme IV
Figure imgf000032_0001
The above amide bond formation can be prepared from coupling of the ester (12 in Scheme IV) with 1 in the presence of trialkylaluminum (such as AIMe3) in an appropriate solvent, eg., THF, toluene or a mixture of THF/toluene in an open or sealed tube at a temperature of between about 80 and about 150°C until complete conversion to the desired product (lb in Scheme IV). SCHEME V
Figure imgf000033_0001
SCHEME VI
Figure imgf000033_0002
The ester group of R7 can be converted to the corresponding amide using a similar method for amide bond formation, preferably using trimethylaluminum in an appropriate solvent or mixture of solvents, such as THF/toluene as shown in Scheme V. The halo group X2 can be generated according to Scheme VI by reacting the starting material wherein R5 is H with NBS, NCS, l2 in an appropriate solvents such as methylene chloride, or chloroform. The halo group can be replaced with another group using the methods known in art, such as halogen-metal exchange, followed by quenching with an electrophile, or using typical Suzuki coupling conditions employing a catalyst such as palladium complex like tetrakis(triphenylphosphine)-palladium with sodium carbonate as a base in a suitable solvent such as THF, DME, Ethanol and a boronic acid.
Regardless of the procedure used to prepare the compounds of formula I, purification may be accomplished by crystallization or using chromatography on silica gel either with an ethyl acetate/hexane elution gradient or a chloroform/methanol elution gradient. Pharmaceutically acceptable salts of a compound of formula I can be prepared in a conventional manner by treating a solution or suspension of the corresponding free base or acid with one chemical equivalent of a pharmaceutically acceptable acid or base. Conventional concentration or crystallization techniques can be employed to isolate the salts. Illustrative of suitable acids are acetic, lactic, succinic, maleic, tartaric, citric, gluconic, ascorbic, benzoic, cinnamic, fumaric, sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, sulfamic, sulfonic acids such as methanesulfonic, benzene sulfonic, p- toluenesulfonic, and related acids. Illustrative bases are sodium, potassium, and calcium.
A compound of this invention may be administered alone or in combination with pharmaceutically acceptable carriers, in either single or multiple doses. Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents. The pharmaceutical compositions formed by combining a compound of formula I or a pharmaceutically acceptable salt thereof can then be readily administered in a variety of dosage forms such as tablets, powders, lozenges, syrups, injectable solutions and the like. These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like. Thus, for purposes of oral administration, tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch, methylcellulose, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration, the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and combinations thereof.
For parenteral administration, solutions containing a compound of this invention or a pharmaceutically acceptable salt thereof in sesame or peanut oil, aqueous propylene glycol, or in sterile aqueous solution may be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
A compound of formula I or a pharmaceutically acceptable salt thereof can be administered orally, transdermally (e.g., through the use of a patch), parenterally (e.g. intravenously), rectally, or topically. In general, the daily dosage for treating a neurodegenerative disease or condition or a disease or condition associated with Aβ-peptide production will generally range from about 0.1 mg/kg to about 5 gm/kg body weight, preferably from about 0.1 mg/kg to about 100 mg/kg body weight. Variations based on the aforementioned dosage range may be made by a physician of ordinary skill taking into account known considerations such as the weight, age, and condition of the person being treated, the severity of the affliction, and the particular route of administration chosen.
A specific compound of formula I can be determined to inhibit Aβ-peptide production using biological assays known to those of ordinary skill in the art, for example the assays described below. The activity of compounds of the invention in inhibiting gamma-secretase activity was determined in a solubilized membrane preparation generally according to the description provided in McLendon et al. Cell-free assays for γ^secretase activity, The FASEB Journal (Vol. 14, December 2000, pp. 2383-2386). Using such assay, compounds of the invention were determined to have an IC 0 activity for inhibiting gamma-secretase activity of less than about 32 micromolar. For example, Example 84, below, had an IC50 of about 1 micromolar, and Example 138, below, had an IC50 of about 5 micromolar. The following Examples illustrate the present invention. It is to be understood, however, that the invention, as fully described herein and as recited in the claims, is not intended to be limited by the details of the following Examples.
Examples General Procedures: Step A: Conversion of L-Norvaline to L-Norvaline-methyl ester.HCL
3.0g (25.6 mmol, 1.0 Eq.) of L-Norvaline was dissolved in 50.0 mL of methanol and cooled to 0 °C. This was saturated with HCI gas and gradually allowed to warm to room temperature. After 14 hours the solvent was removed and the solid was dried overnight in a dessicator with phosphorous pentachloride. 3.6g (86%) of a white solid was obtained. (MS: 126.9/ [P"1]) (H1NMR in CDCI3: 0.95, 3H t, (J=382 Hz), 1.46, 2H m, (J=587 Hz), 2.01 , 2H m, (J=806 Hz), '3.78, 3H s, (J=1512 Hz), 4.05, 1H m, (J=1622.459 Hz), 8.74, 2H brds, (J=3495 Hz))
Step B: Synthesis of 2-r2-(Difluoro-phenyl)-acetyl aminol-pentanoic acid methyl ester
1.0g (7.8 mmol, 1.0 Eq.) of the title compound of Step A was combined in a flask at room temperature with 1.62g (9.4 mmol, 1.2 Eq.) of (3,5-Difluoro-phenyl)-acetic acid, 4.1 g
(9.4 mmol, 1.0 Eq.) of HBTU, 2.6 mL (18.7 mmol, 3.0 Eq.) of triethylamine, and 40 mL of dichloromethane. After stirring overnight at room temperature MS and TLC indicated reaction completion. Solution was extracted successively with 1N HCI, water, saturated sodium bicarbonate, water, and brine. This was dried over sodium sulfate and the solvent removed. The oil obtained was purified by flash chromatography using 4:1 Hexane: Ethyl Acetate as eluent. 800 mg (36%) of the desired product was obtained. (MS: 286.2 [P+1]/284.1 [ 1])
(Rr=0.70 on silica TLC with 1 :1 Hexane/Ethyl Acetate) (H1NMR in CDCI3: 0.84, 3H t, (J=339
Hz), 1.27, 2H m, (J= 510 Hz), 1.60, 1 H m, (J=641.855), 1.773, 1 H m, (J=708.639 Hz), 3.70,
3H s, (J=1478 Hz), 4.57, 1 H m, (J=1828 Hz), 5.91 , 1 H brd d, (J=2362 Hz), 6.69, 1 H m, (J=2677 Hz), 6.78, 2H m, (J=2712 Hz))
Step C: Conversion of 2-f2-(Difluoro-phenyl.-acetyl aminol-pentanoic acid methyl ester to 2-f2-(3.5-Difluoro-phenyl .-acetic acid
800 mg (2.8 mmol, 1.0 Eq.) of the title compound of Step B (2-[2-(difluoro-phenyl)- acetyl aminoj-pentanoic acid methyl ester) was dissolved in a solution of 20 mL H2O/20 mL tetrahydrofuran. 336 mg (14.0 mmol, 5.0 Eq.) of lithium hydroxide was added and this was allowed to stir at room temperature over night. The pH was adjusted to 1.0 with 6.0 N HCI and the solvent was stripped to A the original volume. 700 mg (92 %) of the desired product precipitated out of solution. (MS: 272.2 [P j/270.1 [F1]) (R 0.30 (silica TLC in 9:1 Chloroform/Methanol) (H1 NMR in CD3OD: 0.88, 3H m, (J=354 Hz), 1.41 , 2H m, (J=564 Hz), 1.65, 1 H m, (J=622 Hz), 1.80, 1 H m, (J=721 Hz), 3.55, 2H (J=1420 Hz), 4.32, 1 H m, (J=1728 Hz), 6.80, 1 H m, (J=2721 Hz), 6.90, 2H m, (J=2761 Hz). Step D: Synthesis of N-[1-(5-Amino-3-phenyl-pyrazole-1-carbonyl)-butvn-2-(3,5- diflouro-phenvD-acetamide
220mg (1.38 mmol, 1.25 Eq.) of 5-amino-3-phenyl pyrazole was combined in a flask at room temperature with 595 mg (1.38 mmol, 1.25 Eq.) of HBTU, 0.4 mL ( 3.3 mmol, 3.0 Eq.) of N-methyl piperidine and 8 mL of dichloromethane. After 15 minutes 300 mg (1.1 mmol, 1.0 Eq.) of the product of Step C (2-[2-(3,5-difluoro-phenyl)-acetic acid) was added. MS and TLC indicated reaction completion after 2.5 hours. Solution was extracted successively with saturated sodium bicarbonate, water, and brine, was dried over sodium sulfate, and the solvent removed. The yellow solid obtained was purified by flash using 3:1 Hexane/Ethyl Acetate yielding.260 mg (57%) of a white solid. (MS: 413.1 [P+1]/ 411.1 [F1]) (R O.69 (silica TLC in 1 :1 Hexane/Ethyl Acetate)) (H1NMR in CD30D: 0.95, 3H m, (J=380 Hz), 1.48, 2H m, (J=595 Hz), 1.97, 2H m, (J=789 Hz), 3.60, 2H s, (J=1439 Hz), 5.45, 1 H s, (J=2180 Hz), 5.74, 1 H m, (J=2296 Hz), 6.90, 1 H m, (J=2760 Hz), 6.92, 2H m, (J=2767 Hz), 7.33, 5H m, (J=2933 Hz), 7.75, 2H d, (J=3100 Hz))
Step E: Rearrangement of N-H-(5-Amino-3-phenyl-pyrazole-1-carbonyl)-butvπ-2-(3,5- diflouro-phenvD-acetamide to 2-r2-(3,5-Difluoro-phenyl)-acetylaminel-pentanoic acid (5- phenyl-2H-pyrazole-3-yl, -amide
260 mg of the title compound of Step D (N-[1-(5-amino-3-phenyl-pyrazole-1- carbonyl)-butyl]-2-(3,5-diflouro-phenyl)-acetamide) was heated neat to 150 °C. After 2 hours LC/MS indicated reaction completion. The solid was tritrated with hexane to give 240 mg of final product. (R O.45 (silica TLC in 1 :1 Hexane/Ethyl Acetate) (H1NMR in CD3OD: 0.93, 3H t, (J=372 Hz), 1.42, 2H m, (J=480 Hz), 1.67, 1 H m, (J=520 Hz), 1.72, 1H m, (J=532 Hz), 3.59, 2H s, (J=1435 Hz), 4.23, 1 H m, (J=1678 Hz), 6.79, 3H m, (J=2714.266 Hz), 6.90, 2H m, (J=2759 Hz), 7.37, 2H m, (J=2949 Hz), 7.39, 1 H m, (J=2957 Hz), 7.39, 2H d, (J=2957 Hz))
Procedure for 2-f2-(3,5-Difluoro-phenyl)-acetylamino1-penatnoic acid (5-phenyl-2H- p yrazo le-3-yl )-am ide :
Step A: Synthesis of ri-(5-Amino-3-phenyl-pyrazole-1-carbonyl)-butyll-carbamic acid tert-butyl ester
492 mg (2.26 mmol, 1.2 Eq.) of boc-norvaline was combined in a flask with 300 mg (1.9 mmol, 1.0 Eq.) of 5-amino-3-phenyl pyrazole, 0.80 mL (5.7 mmol, 3.0 Eq.) of triethylamine, 820 mg (1.9 mmol, 1.0 Eq.) of HBTU and 10 mL of anhydrous dichloromethane. After one hour of room temperature stirring MS and TLC indicated reaction completion. Solution was extracted with saturated sodium bicarbonate followed by water and brine. This was dried over sodium sulfate and the solvent removed. The yellow oil obtained was purified by flash chromatography using 3:1 Hexane/Ethyl Acetate as the solvent. 471 mg (69%) of yellow oil was obtained. (MS: 359/[P+1]) (Rf=0.89 on silica TLC with 1 :1 Hexane/Ethyl Acetate) (H1NMR in CD3OD: 0.95, 3H t, (J=383 Hz), 1.22, 9H s, (J=488 Hz), 1.41 , 2H m, (J=567 Hz), 1.97, 2H m, (J=790 Hz), 5.40, 1 H m, 5.75, 1 H s, (J=2299 Hz), 7.35, 3 H m, (J=2938 Hz), 7.79, 2H m, (J=3115 Hz).
Step B: Rearrangement/BOC Removal to give 2-Amino-1-(5-amino-3-phenyl- pyrazole-1-yl)-pentan-1-one Di-HCI Salt
471 mg of the title compound of Step A (ι[1-(5-amino-3-phenyl-pyrazole-1-carbonyl)- butylj-carbamic acid tert-butyl ester) was taken up in 4.5 mL of a 4.0 N HCI dioxane solution and allowed to stir at room temperature. After 1 hour MS indicated reaction completions. The solvent was removed and the residue obtained was titrated with ether to give 250 mg (73%) of a white solid. (MS: 259.2 [P+1]) (H1NMR in DMSO: 0.87, 2H m, (J=350 Hz), 1.02, 3H t, (J=409 Hz), 1.29, 1 H m, (J=518 Hz), 1.72, 1 H m, (J=691 Hz), 3.51 , 1 H m, (J=1406 Hz), 6.86, 1 H s, (J=2742 Hz), 7.41 , 3H m, (J=2962 Hz), 7.67, 1H d, (J=3068 Hz), 7.37, 1 H d, (J=3095 Hz), 8.23, 2H d, (J=3291 Hz).
Step C: Synthesis of 2-f2-(3,5-Difluoro-phenyl)-acetylamino1-pentanoic acid (5- phenyl-2H-pyrazole-3-yl)-amide
160 mg (0.62 mmol, 1.0 Eq.) of the title compound of Step C (2-amino-1-(5-amino-3- phenyl-pyrazole-1-yl)-pentan-1-one Di-HCI) was combined in a flask with 128 mg (0.74 mmol, 1.2 Eq.) of 3,5-Difluoro-phenyl acetic acid, 0.31 mL (2.2 mmol, 3.0 Eq.) of triethylamine, 267 mg (0.62 mmol, 1.0 Eq.) of HBTU and 10 mL of anhydrous dichloromethane. After 2 hours of room temperature stirring MS and TLC indicated reaction completion. Desired product was confirmed by H1NMR and LC/MS. Procedure for 2-Phenylmethanesulfonylamino-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide:
Step A: Coupling of BOC-Ala with Aminopyrazole to afford H -(5-Phenyl-2H-pyrazol- 3-ylcarbamoyl)-ethvπ-carbamic acid tert-butyl ester:
To 348 mg (2.2 mmol) of 5-phenyl-2Hpyrazol-3-ylamine (or its corresponding tautomer 5-phenyl-1 H-pyrazol-3-ylamine) and 378 mg (2mm9l) of BOD-L-alanine (Aldrich) in 4 ml of methylene chloride was added at 0° C dropwise with stirring 0.61 ml (4.4 mmol) of thriethylamine, followed by 0.33 ml (3.3 mmol) of diethylcyanophosphonate after 20 min. The reaction was allowed to warm to room temperature and stirred for 24 hr. After determination that the reaction had proceeded to completion by TLC and mass spectroscopy, the methylen chloride was evaporated and the residue dissolved in ethylacetat. The organic layer was washed successively with 1 N Hcl, SATD NaHC03, and brine, followed by drying with sodium sulfate. Evaporation yielded 770 mg of 1-(5-Phenyl-2H-pyrazol-3-ylcarbamoyl)-ethyl]- carbamic acid tert-butyl ester
(quantitative) ( MS: 331 P+1/329 P-1) (RF = 0.6 ON SILICA TLC (9/1 Chloroform/ Methanol). Step B: Deblocking of 1-(5-Phenyl-2H-pyrazol-3-ylcarbamoyl)-ethyl1-carbamic acid tert-butyl ester to Amino-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide Dihydrochloride
To 100 mg (0.30 mmol) of the product of Step A [1-(5-phenyl-2H-pyrazol-3- ylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester was added 1 ml of 4N HCI dioxane solution (Aldrich) at ambient temperature. The reaction was allowed to stir for 3 hours. After evaporation to dryness and trituration with ether, 73 mg of amino-N-(5-pheny!-2H-pyrazol-3- yl)-propionamide dihydrochloride was obtained as a white powder ( 80%) ( MS: 231 [P+1] / 229 [P-1] )(RF = 0.2 on silica TLC (9/1 Chloroform/ Methanol).
Step C: Coupling of Benzylsulfonylchloride with amino-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide dihydrochloride to afford Phenylmethanesulfonylamino-N-(5-phenyl-2H-pyrazol- 3-yl)-propionamide
To 73 mg of the produce of Step B (amino-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide dihydrochloride) (0.24 mmol), triethylamine (0.10 ml, 0.72 mmol) in 2 ml of methylene chloride at 0° C with stirring was added 46 mg (0.24 mmol) of benzyl sulfonyl chloride. After 1 hour the reaction was allowed to warm to ambient and stirred for 19 hours. Mass spectroscopy had indicated that the reaction had proceeded to completion. Using the workup procedure of Step A by trituration with ether yeilded 32 mg of pure phenylmethanesulfonylamino-N-(5-phenyI-2H-pyrazol-3-yl)-propionamide 7 (35%) (MS: 385[P+1}/383[P-1]) (RF= 0.75 (silica gel TLC with CHCIs/CHsOH 18/1)).
The following Examples of compounds of Formula I of the invention were prepared according to Schemes l-VI in the "Detailed Description of the Invention":
Table 1
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
Figure imgf000051_0001
Figure imgf000052_0001
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
Figure imgf000057_0001
Table 2
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0001
Table 3
Figure imgf000061_0001

Claims

1. A compound of Formula
Figure imgf000062_0001
or a pharmaceutically acceptable salt thereof, wherein:
A is selected from -C(=0)C(=0)-, -C(=0)Z-, -C(=S)Z-,C(=NR5)Z-, and -S(0)2-; wherein Z is -CH2-, -CH(OH)-, -CH(OC(=0)R11)-, -CH(NH2)-, -CH(CH2(OH))-, -CH(CH(C C4 alkyl)(OH))-, or -CH(C(C C4 alkyl)(C C4 alkyl)(OH))-;
R1 is selected from C C20 alkyl and -C-ι-C2o alkoxy, C3-C8 cycloalkyl, (C4- C8)cycloalkenyl, (Cs-C-i bi- or tricycloalkyl, (C7-Cn)bi- or tricycloalkenyl, (3-8 membered) heterocycloalkyl, (C6-C14)aryl, or (5-14 membered) heteroaryl, wherein said alkyl and alkoxy each optionally contains from one to five double or triple bonds, and wherein each hydrogen atom of said alkyl and alkoxy is optionally replaced with a fluorine; wherein when R1 is alkyl or alkoxy, R1 is optionally substituted with from one to three substituents R1a, and wherein when R1 is cycloalkyl, cycloalkenyl, bi- or tricycloalkyl, bi- or tricycloalkenyl, heterocycloalkyl, aryl, or heteroaryl, then R1 is optionally substituted with from one to three substituents R1b;
R1a is in each instance independently selected from -OH, -Cι-C6 alkyl independently optionally containing from one to three double or triple bonds, -C C6 alkoxy independently optionally containing from one to three double or triple bonds, -CI, -F, -Br, -I, -CN, -N02, -NR9R10, -C(=0)NR9R10, -S(0)nNR9R10, -C(=0)R11, -S(0)nR11, -C(=0)OR12, -C3-C8 cycloalkyl, -C -C8 cycloalkenyl, -(Cs-CnJbi- or tricycloalkyl, -(Cr-C^bi- or tricycloalkenyl, -(3-8 membered) heterocycloalkyl, -(C6-C1 )aryl, -(5-14 membered) heteroaryl, -(C6-C1 ) aryloxy, and -(5-14 membered) heteroaryloxy, wherein said alkyl, alkoxy, cycloalkyl, cycloalkenyl, bi- or tricycloalkyl, bi- or tricycloalkenyl, heterocycloalkyl, aryl, heteroaryl, aryloxy, and heteroaryloxy are each independently optionally substituted with from one to three substituents R1b;
R1b is in each instance independently selected from -CI, -F, -Br, -I, -CN, -N02, -(Czero- C4 alkylene)-NR9R10, -(Czera-C4 alkylene)-C(=)ONR9R10, -(Czero-C4 alkylene)-C(=0)R11, -(Czero- C4 alkylene)-C(=0)OR12, -(C_ero-C4 alkylene)-S(0)nR11, -(Czero-C4 alkylene)-S(0)nNR9R10, -(Czero-C4 alkyleneyOH.-CrC. alkyl independently optionally containing from one to three double or triple bonds, -C C6 alkoxy independently optionally containing from one to three double or triple bonds, -C-rC, hydroxyalkyl, -(C6-C14) aryloxy, -(5-14 membered) heteroaryloxy, -(C6-C1 ) aryl, -(5-15 membered) heteroaryl, and -C C6 alkyl independently optionally containing from one to three double or triple bonds and independently substituted with from one to six atoms independently selected from F, CI, Br, and I;
R2 is selected from -H, -C C alkyl optionally containing one or two double or triple bonds, -C(=0)(C-,-C4 alkyl), -C6-C10 aryl, -SO2-(C6-C10 aryl), and -Sθ2-CH2-(C6-C10 aryl), and R2 is optionally substituted with from one to three substituents R1b;
R3 is selected from C^Ce alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -(Czero-C4 alkylene)- (C3-C6 cycloalkyl), and -(Czera-C4 alkylene)-(C3-C6 cycloalkenyl), wherein said alkyl, alkenyl and alkynyl are each optionally substituted with a substituent selected from -OH, C C4 alkoxy, and -S-(C C4 alkyl);
R4 is H, D, F, or d-C4 alkyl; or R3 and R4 may together optionally form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, morpholino, piperidino, or perhydro-2H-pyran moiety, wherein said moiety formed by R3 and R4 is optionally substituted with one to three substituents independently selected from -OH, -CI, -F, -CN, -CF3, methyl, ethyl, methoxy, ethoxy, allyl, and -OCF3;
R5 is selected from -H, -C C6 alkyl optionally substituted with from one to three R1a groups, and -C6-C10 aryl optionally substituted with from one to three R1a groups; or R5 and R1 may together optionally form a five to fourteen membered heteroaryl ring or a five to eight membered heterocycloalkyl ring, wherein said heteroaryl or heterocycloalkyl ring optionally contains one or two further heteroatoms selected from N, O, and S, and wherein said heterocycloalkyl ring optionally contains from one to three double bonds, and wherein said heteroaryl or heterocycloalkyl ring is optionally substituted from one to three R1b substituents;
R6 is selected from -H, -C C20 alkyl, -CI, -F, -Br, -I, -CN, -CF3, -C(=0)R11, -C(=0)OR12, -S(0)nNR9R10, -S(0)nR11, -C(=NR9)R15, -(C3-C12) cycloalkyl, -(C4-C12) cycloalkenyl, and -C6-C10 aryl, wherein said alkyl, alkylene, cycloalkyl, cycloalkenyl, and aryl of R6 are each optionally substituted with from one to three R1b substituents;
R7 is selected from H, -CI, -F, -Br, -I, -CN, -N02, -NR14R15, -CF3, -C(=0)NR14R15,
-C(=0)R13, -S(0)nR13,-C(=0)OR13, -C(=NR9)R , -S(0)nNR14R15, -C C20 alkyl, -C C 20 alkoxy, -(Czero-C4 alkylene)-(C3-C12 cycloalkyl), -(Czero-C4 alkylene)-((C4-C12)cycloalkenyl), -(Czero-C4 alkylene)-((C5-C20)bi- or tricycloalkyl), -(Czera-C4 alkylene)-((C7-C20)bi- or tricycloalkenyl), -(Czero-C4 alkylene)-((3-12 membered) heterocycloalkyl), -(Czero-C4 alkylene)- ((7-20 membered) heterobi- or heterotricycloalkyl), -(Czero-C4 alkylene)-((C6-C14)aryl), and -(Czero-C4 alkylene)-((5-15 membered) heteroaryl); wherein R7 is optionally substituted with from one to three substituents independently selected from R1a, -(CH2)1.10NR9R10, -C3-C 2 cycloalkyl, -((4-12 membered) heterocycloalkyl), -(C6-C14) aryl, -((5-15 membered) heteroaryl), -(4-12 membered) heterocycloalkoxy), -(C6-C12) aryloxy and -((5-12 membered) heteroaryloxy); said cycloalkyl, cycloalkenyl, bi- or tricycloalkyl, bi- or tricycloalkenyl, heterocycloalkyl, aryl, and heteroaryl of R7 are each optionally and independently substituted with from one to six F; said alkyl, alkoxy, and alkylene of R7 each optionally contains from one to five double or triple bonds; and each hydrogen atom of said alkyl, alkoxy, and alkylene of R7 is independently optionally replaced with a fluorine; or R6 and R7 or R7 and its proximate nitrogen atom may together optionally form a -(C6-C10) aryl ring, -(C6-C8) cycloalkyl or cycloalkenyl ring, a five to eight membered heterocycloalkyl or heterocycloalkenyl ring, a -(C10-Cι ) membered bicycloalkyl or bicycloalkenyl ring, or a ten to fourteen membered bicycloheteroalkyl or bicycloheteroalkenyl ring fused to the pyrazole ring of Formula I, wherein from one to three members of said heterocycloalkyl and heterocycloalkenyl rings, and from one to five members of said bicycloheteroalkyl and bicycloheteroalkenyl rings are selected independently from N, O and S, and wherein said aryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, bicycloalkyl, bicycloalkenyl, bicycloheteroalkyl, and bicycloheteroalkenyl rings optionally are substituted with from one to three R1b groups;
R8 is selected from -H, -C C4 alkyl, -CI, -F, -Br, -I, -CN, -CF3, -C(=0)R11, -C(=0)OR12, and -C6-C10aryl, with the proviso that the pyrazole ring is always aromatic and that R8 is attached to either ring nitrogen;
R9 and R10 are each independently selected from -H, -OH, -Cι-C6 alkyl independently optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with a fluorine, -C-|-C6 alkoxy independently optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with a fluorine, -C(=0)R11, -S(0)nR11, -C(=0)OR12, -S(0)nNR11R12, -(Czero-C4 alkylene)-(C3-C8 cycloalkyl), -(Czsro-C4 alkylene)-(C4-C8 cycloalkenyl), -(Czero-C4 alkylene)-((C5-C11)bi- or tricycloalkyl), -(Czero-C4 alkylene)-((C7-Cn)bi- or tricycloalkenyl), -(Czera-C4 alkylene)-(C6-C14 aryl), -(Czera-C4 alkylene)-(3-8 membered heterocycloalkyl), and -(Czer0-C4 alkylene)-(5-14 membered heteroaryl), wherein said cycloalkyl, cycloalkenyl, bi-or tricycloalkyl, bi- or tricycloalkenyl, aryl, heterocycloalkyl, and heteroaryl are each optionally independently substituted with from one to three substituents independently selected from -CI, -F, -Br, -I, -CN, -N02, -NR14R15, -C(=)ONR14R15, -C(=0)R11, -C(=0)OR12, -S(0)nR11, -S(0)nNR14R15, -OH, -CrC6 alkyl independently optionally containing from one to three double or triple bonds, -C C6 alkoxy independently optionally containing from one to three double or triple bonds, -C-τC-6 hydroxyalkyl, -(C6-C14) aryloxy, -(5-14 membered) heteroaryloxy, -(Czero-C4)-((C6-C1 ) aryl), -(Czero-C4)-(5-14 membered heteroaryl), and -C-ι-C6 alkyl independently optionally containing from one to three double or triple bonds and independently substituted with from one to six atoms independently selected from F, CI, Br, and I; or NR9R10 can independently optionally form a heterocycloalkyl moiety of from four to seven ring members, said heterocycloalkyl moiety independently optionally comprising one or two further heteroatoms independently selected from N, O, and S, and independently optionally containing from one to three double bonds, and said heterocycloalkyl moiety independently optionally substituted with from one to three substituents independently selected from -CI, -F, -Br, -I, -CN, -N02, -NR14R15, -C(=)ONR1 R15, -C(=0)R11, -C(=0)OR12, -S(0)nR11, -S(0)nNR1 R15, -OH, -C Cβ alkyl independently optionally containing from one to three double or triple bonds, -Cι-C6 alkoxy independently optionally containing from one to three double or triple bonds, -Cι-C6 hydroxyalkyl independently optionally containing from one to three double or triple bonds, -(C6-Cι4) aryloxy, -(5-14 membered) heteroaryloxy, -(Czero-C4)-((C6-C14) aryl), -(CZΘro-C4)-(5-14 membered heteroaryl), and -Ci-Ce alkyl independently optionally containing from one to three double or triple bonds and independently substituted with from one to six atoms independently selected from F, CI, Br, and I;
R11 and R12 are each independently selected from H, -C C6 alkyl, -(Czero-C4 alkylene)- (C3-C8 cycloalkyl), -(Czero-C4 alkylene)-(C4-C8 cycloalkenyl), -(Czero-C4 alkyIene)-((C5-C11)bi- or tricycloalkyl), and -(Czero-C4 alky!ene)-((C7-C1ι)bi- or tricycloalkenyl), -(Czero-C4 alkylene)-(C6- C10 aryl), -(Czero-C4 alkylene)-((3-8 membered) heterocycloalkyl), and -(Czera-C4 alkylene)-((5- 14 membered) heteroaryl), and R11 and R12 are independently optionally substituted with from one to three R1b; R13 is selected from H, -C C6 alkyl optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with a fluorine, -(Czero-C alkylene)-(C3-C12 cycloalkyl), -(Czero-C4 alkylene)-(C4-C12 cycloalkenyl), -(CZΘro-C4 alkylene)-((C5-C20)bi- or tricycloalkyl), and -(Czero-C4 alkylene)-((C7-C20)bi- or tricycloalkenyl), -(Czero-C4 alkylene)-(C6-C14 aryl), -(Czera-C4 alkylene)-((3-12 membered) heterocycloalkyl), -(Czero-C4 alkylene)-((7-20 membered) heterobi- or heterotricycloalkyl), and -(C2er0-C4 alkylene)- ((5-14 membered) heteroaryl), and R13 is optionally substituted with from one to three substituents R1b;
R14 and R15 are each independently selected from -H, -d-C^ alkyl independently optionally containing from one to five double or triple bonds and wherein each hydrogen is independently optionally replaced with a fluorine, -C(=0)R11, -S(0)nR11, -C(=0)OR12, -S(0)nNR11R12, -(Czera-C4 alkylene)-(C3-C12 cycloalkyl), -(Czero-C4 alkylene)-(C4-C12 cycloalkenyl), -(Czera-C4 alkylene)-((C5-C20)bi- or tricycloalkyl), -(Czero-C4 alkylene)-((C7-C20)bi- or tricycloalkenyl), -(Czero-C4 alkylene)-(C6-C14 aryl), -(Czero-C4 alkylene)-(3-8 membered heterocycloalkyl), and -(Czero-C4 alkylene)-(5-14 membered heteroaryl), wherein said cycloalkyl, cycloalkenyl, bi-or tricycloalkyl, bi- or tricycloalkenyl, aryl, heterocycloalkyl, and heteroaryl are each independently optionally substituted with from one to three substituents independently selected from -CτC6 alkyl independently optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with fluorine, -CI, -F, -Br, -I, -CN, -N02, -NH2, -OH, -C(=0)H, -S(0)nH, -C(=0)OH, -C(=0)NH2, -S(0)nNH2, -C C6 alkoxy independently optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with fluorine, -C C6 hydroxyalkyl independently optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with fluorine, -(5-14 membered) heteroaryloxy, -(C6-C14 aryloxy), -(Czera-C4 alkylene)-(C6-C14 aryl), -(Czero-C4 alkylene)-((5-14 membered) heteroaryl), and -Cι-C6 alkyl independently substituted with from one to six atoms independently selected from F, CI, Br, and I and independently optionally containing from one to three double or triple bonds; or NR14R15 can independently optionally form a heterocycloalkyl moiety of from four to seven ring members, said heterocycloalkyl moiety independently optionally comprising one or two further heteroatoms independently selected from N, O, and S, and independently optionally containing from one to three double bonds, and said heterocycloalkyl moiety independently optionally substituted with from one to three substituents independently selected from -C Ce alkyl independently optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with fluorine, -CI, -F, -Br, -I, -CN, -N02, -NH2, -OH, -C(=0)H, -S(0)nH, -C(=0)OH, -C(=0)NH2, -S(0)nNH2, -C C6 alkoxy independently optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with fluorine, -C C6 hydroxyalkyl independently optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with a fluorine, -(5-14 membered) heteroaryloxy, -(C6-C14 aryloxy), -(Czera-C4 alkylene)-(C6-C14 aryl), -(Czero-C alkylene)-((5-14 membered) heteroaryl), and -C-|-C6 alkyl independently optionally containing from one to three double or triple bonds and independently substituted with from one to six atoms independently selected from F, CI, Br, and I; and n is in each instance an integer independently selected from zero, 1 , 2, and 3.
2. A compound according to Claim 1 , wherein A is -C(=0)Z- or -C(=0)C(=0)-.
3. A compound according to Claim 2, wherein Z is -CH2- or -CH(OH)-.
4. A compound according to any of Claims 1 , 2, or 3, wherein R3 is allyl, methyl, ethyl, n-propyl, n-butyl, /-butyl, s-butyl, or-CH2CH2SCH3.
5. A compound according to any of Claims 1-4, wherein R6 is selected from hydrogen, methyl, ethyl, -F, -CI, -Br, and -CF3.
6. A compound according to any of Claims 1-5 wherein R is -C2-C12 alkyl, C3- C8 cycloalkyl, (C5-C8)cycloalkenyl, -(Cs-C-nJbi- or tricycloalkyl, -(C7-C-ι1)bi- or tricycloalkenyl,
(3-8 membered) heterocycloalkyl), -(C6-C10)aryl, -(5-10 membered) heteroaryl, or CτC4 alkyl substituted with R1a wherein R1a is -(C6-C10)aryl or -(5-10 membered) heteroaryl.
7. A compound according to any of Claims 1-6 wherein R is straight-chain C2- C10 alkyl or branched C3-C10 alkyl.
8. A compound according to any of Claims 1-5, wherein R1 is selected from phenyl, thienyl, and pyridyl, optionally and independently substituted with one or two substituents R1b.
9. A compound according to any of Claims 1-8, wherein R7 is selected from -H, -C C12 alkyl optionally containing from one to five double bonds and wherein each hydrogen is independently optionally replaced with a fluorine, -C C20 alkoxy optionally containing from one to five double bonds and wherein each hydrogen is independently optionally replaced with a fluorine, -F, -CI, -Br, -I, -CN, -N02, -(C3-C12) cycloalkyl optionally substituted with from one to six fluorine, -((3-12 membered) heterocycloalkyl) optionally substituted with from one to six fluorine, -(C6-C14) aryl, -((5-15 membered) heteroaryl), -CHO, -C(=0)(C1-C15 alkyl), -C(=0)((5-12 membered)heterocycloalkyl), -C(=0)(C6-C14 aryl), -C(=0)((5-15 membered) heteroaryl), -C(=0)(C5-C12 cycloalkyl), -C(=0)0(C C8 alkyl), -C(=O)N(Cι-C10 alkyl)(C1-C10 alkyl), -C(=O)N(C1-C10 alkyl)(C6-C10 aryl), -C(=O)NH(C6-C10 aryl), -C(=O)N(C C10 alkyl)((5-10 membered) heteroaryl), -C(=O)NH((5-10 membered) heteroaryl), -C(=O)N(C1-C10 alkyl)((5-10 membered) heterocycloalkyl), -C(=O)NH((5-10 membered) heterocycloalkyl), -C(=O)N(C C10 alkyl)(C5-C10 cycloalkyl), -C(=O)NH(C5-C10 cycloalkyl), -S(0)n(C1-C15 alkyl), -S(0)n(C5-C12 cycloalkyl), -S(0)n(C6-C15 aryl), -S(O)n((5-10 membered) heteroaryl), wherein said alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each optionally independently substituted with from one to three substituents independently selected from -F, -CI, -Br, -I, -OH, -Cι-C6 alkoxy independently optionally containing from one to three double or triple bonds, -NR9R10, -(CH^ONR'R10, -C(=0)R11, -S(0)nR11, -C(=0)OR11, -C(=0)NR9R1°, -S(0)nNR9R1° -(C3-C12) cycloalkyl, -((4-12 membered) heterocycloalkyl), -(C6-C15) aryl, -((5-15 membered) heteroaryl), -((4-12 membered) heterocycloalkoxy), -(C6-C12) aryloxy and -((6-12 membered) heteroaryloxy).
10. A compound according to Claim 9, wherein R7 is selected from -C1-C12 alkyl optionally comprising from one to five double bonds and wherein each hydrogen is independently optionally replaced with a fluorine, -(C3-C12) cycloalkyl optionally substituted with from one to six fluorine, and -((3-12 membered) heterocycloalkyl) optionally substituted with from one to six fluorine, wherein said alkyl, cycloalkyl and heterocycloalkyl are each optionally independently substituted with from one to three substitutents independently selected from -OH, -Ct-C6 alkoxy independently optionally containing from one to three double or triple bonds, -NR9R10, -(CH^NR 0, -C(=0)R11, -C(=0)OR11, -C(=0)NR9R10, -S(O)nNR9R10,-(C6-C15) aryl, -((5-15 membered) heteroaryl), -((4-12 membered) heterocycloalkoxy), -(C6-C12) aryloxy and -((6-12 membered) heteroaryloxy).
11. A compound according to claim 1 selected from the group consisting of: 2-(2-benzo[b]thiophen-4-yl-acetylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide; N-(5-phenyI-2H-pyrazol-3-yl)-2-(2-thiophen-2-yl-acetylamino)-propionamide; 2-[2-(4-fluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H-pyrazoI-3-yl)- propionamide; 2-[2-(4-chloro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide;
N-(5-phenyl-2H-pyrazol-3-yl)-2-(2-m-tolyl-acetylamino)-propionamide; 2-[2-(2,5-difluoro-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide; 2-[2-hydroxy-2-(4-trifluoromethyl-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide;
2-(2-fluoro-2-phenyl-acetylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide; N-(5-phenyl-2H-pyrazol-3-yl)-2-[2-(4-trifluoromethyl-phenyl)-acetylamino]- propionamide;
2-[2-(2-fluoro-5-trifluoromethyl-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide;
2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide;
N-(5-phenyJ-2H-pyrazol-3-yl)-2-[2-(2-trifluoromethoxy-phenyl)-acetylamino]- propionamide; 2-[2-(3-phenoxy-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
N-(5-phenyl-2H-pyrazol-3-yl)-2-[2-(4-trifluoromethoxy-phenyl)-acetylamino]- propionamide;
2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyI-2H-pyrazol-3-yl)- propionamide; acetic acid (3,5-difluoro-phenyl)-[1-(5-phenyl-2H-pyrazoI-3-ylcarbamoyl)- ethylcarbamoylj-methyl ester;
2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyI-2H-pyrazol-3-yl)- propionamide;
2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide;
2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- butyramide;
2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H-pyrazoI-3-yl)- butyramide; N-(5-phenyl-2H-pyrazol-3-yl)-2-(2-pyridin-3-yl-acetyIamino)-butyramide;
N-(5-phenyl-2H-pyrazol-3-yl)-2-(2-pyridin-2-yl-acetyIamino)-butyramide; 2-[2-(5-bromo-pyridin-3-yl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide; 2-(3-cyclopentyl-propionylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide; 2-phenyl-cyclopropanecarboxylic acid [1 -(5-phenyl-2H-pyrazol-3-ylcarbamoyl)- propylj-amide;
N-[1-(5-phenyI-2H-pyrazol-3-ylcarbamoyl)-propyl]-succinamic acid methyl ester; 3,3-dimethyI-N-[1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propyl]-butyramide; dodecanoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propyl]-amide; 2-phenylacetylamino-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide; hexanoic acid [1 -(5-phenyl-2H-pyrazoI-3-ylcarbamoyl)-propyl]-amide; heptanoic acid [1 -(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propyl]-amide; 2-(3-chloro-propionylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
2-(3-phenyl-propionylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide; 3-methyl-N-[1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propyl]-butyramide; decanoic acid [1 -(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propyl]-amide; 2-butyrylamino-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide; 5-chloro-pentanoic acid [1-(5-phenyI-2H-pyrazol-3-ylcarbamoyl)-propyl]-amide;
2-[2-(3-phenoxy-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide; 3-{[1-(5-phenyl-2H-pyrazol-3-ylcarbamoyI)-propylcarbamoyl]-methyl}-piperidine-1- carboxylic acid tert-butyl ester;
N-(5-phenyl-2H-pyrazoI-3-yl)-2-[2-(3-trifluoromethyl-phenyl)-acetylamino]-butyramide; 2-[2-(3-iodo-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
2-[2-(3-chloro-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide; 4-methylsulfanyl-2-[2-(3-phenoxy-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazoI-3-yl)- butyramide;
2-hydroxy-4-methyl-pentanoic acid [3-methylsulfanyl-1 -(5-phenyl-2H-pyrazol-3- ylcarbamoyl)-propyl]-amide;
2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-4-methylsulfanyl-N-(5-phenyl-2H- pyrazol-3-yl)-butyramide;
2-acetylamino-4-methylsuIfanyl-N-(5-phenyl-2H-pyrazol-3-yl)- butyramide; 5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid ethyl ester;
5-[2-(2-hydroxy-4-methyl-pentanoylamino)-butyrylamino]-1 H-pyrazole-3- carboxylic acid ethyl ester;
5-{2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-butyrylamino}-1H-pyrazole-3- carboxylic acid ethyl ester; 2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-(5-hydroxymethyl-2H-pyrazol-3-yl)- butyramide; 2-[2-(3,5-difIuoro-phenyl)-acetylamino]-N-(5-hydrazinocarbonyl-2H-pyrazol-3-yl)- butyramide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-[5-(5-phenyl-4H-[1 ,2,4]triazol-3-yl)-2H- pyrazol-3-yl]-butyram ide; 2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-(4-oxo-4,5-dihydro-pyrazolo[1 ,5- d][1 ,2,4]triazin-2-yl)-butyramide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-(4-methoxy-7-phenyl- pyrazolo[1 ,5-d][1 ,2,4]triazin-2-yl)-butyramide;
5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole- 3-carboxylic acid amide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-(4-oxo-7-phenylsulfanylmethyl-4,5-dihydro- pyrazolo[1 ,5-d][1 ,2,4]triazin-2-yl)-butyramide;
5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid methylamide; 5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid (l-ethyl-propyl)-amide;
5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole- 3-carboxylic acid butyl-ethyl-amide;
5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid cyclopropylmethyl-amide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-[5-(morpholine-4-carbonyl)-2H-pyrazol-3-ylj- butyramide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-[5-(pyrrolidine-1-carbonyl)-2H-pyrazol-3-yl]- butyramide; 5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid piperidin-1-ylamide;
5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid sec-butyl-amide;
5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid ethyl-(2-hydroxy-ethyl)-amide;
5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid cyclohexyl-ethyl-amide;
5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid diallylamide; 2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide; 2-[2-(3,5-difluoro-phenyl)-acetylamino]-3-methyl-pentanoic acid (5-phenyl-2H-pyrazol- 3-yl)-amide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-3-methyl-pentanoic acid (5-butyl-2H-pyrazol-3- yl)-amide; 2-phenylacetylamino-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
2-[2-(3-fluoro-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
2-[2-(3,5-bis-trifluoromethyl-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide;
5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionylamino}-1H-pyrazole-3-carboxylic acid butyl ester;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-[5-(1 H-indol-3-yl)-2H-pyrazol-3-ylj- propionamide;
N-[5-(4-tert-butyl-phenyl)-2H-pyrazol-3-yl]-2-[2-(3,5-difluoro-phenyl)-acetylaminoj- propionamide; 2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-[5-(4-ethyl-phenyl)-2H-pyrazol-3-yl]- propionamide;
5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionylamino}-1 H-pyrazole-3-carboxylic acid ethyl ester;
N-(4-bromo-5-phenyl-2H-pyrazol-3-yl)-2-[2-(3,5-difluoro-phenyl)-acetylamino]- propionamide;
1 -[2-(3,5-difluoro-phenyl)-acetylamino]-cyclopentanecarboxylic acid (5-phenyl-2H- pyrazol-3-yl)-amide;
N-(4-ChIoro-5-phenyl-2H-pyrazol-3-yl)-2-[2-(3,5-difluoro-phenyl)-acetylamino]- propionamide; 2-[2-(3,5-difluoro-phenyl)-acetylamino]-pent-4-enoic acid (5-phenyl-2H-pyrazol-3-yl)- amide; t(5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionylamino}-1 H-pyrazole-3-carbonyl)- aminoj-phenyl-acetic acid tert-butyl ester;
5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionylamino}-1 H-pyrazole-3-carboxylic acid benzylamide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-pent-4-enoic acid (4-bromo-5-phenyl-2H- pyrazol-3-yI)-amide;
5-{2-[2-(3,5-difIuoro-phenyl)-acetylamino]-propionyIamino}-1 H- pyrazole-3-carboxylic acid methyl ester; 2-[2-(3,5-difluoro-phenyl)-acetylamino]-2-phenyl-N-(5-phenyl-2H-pyrazol-3-yl)- acetamide; 2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-pent-4-enoic acid (5-phenyl-2H- pyrazol-3-yl)-amide;
3-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- succinamic acid methyl ester; 2-cyclohexyl-2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- acetamide;
2-cyclohexyl-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H- pyrazol-3-yl)-acetamide;
3-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H- pyrazoI-3-yl)- succinamic acid benzyl ester;
2-(2-hydroxy-2-phenyl-acetylamino)-pent-4-enoic acid (5-thiophen-2-yl-2H-pyrazol-3- yl)-amide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-pentanoic acid (5-methyl-1-phenyl-1 H-pyrazol- 3-yl)-amide; 2-(2-bicyclo[2.2.1]hept-2-yl-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)- amide;
2-(2-cyclohexyl-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3- yl)-amide;
2-(3-hydroxy-2-phenyl-propionylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)- amide; 2-(2-adamantan-1-yl-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
4-methyl-pentanoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)- butylj-amide;
3-methyl-pentanoic acid [1 -(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide;
2-(2-cyclopentyl-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)- amide;
2-(2-cyclopropyl-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide; 2-(2-indan-2-yl-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
2-(3-phenyl-butyrylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
5-oxo-hexanoic acid [1 -(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide;
2-[2-(3-chloro-phenyl)-acetylamino]-pentanoic acid (5-phenyl-2H-pyrazol-3-yI)-amide;
2-[2-(3-bromo-phenyl)-acetylamino]-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide; 2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-(5-furan-2-yl-2H-pyrazol-3-yl)-propionamide;
N-(5-tert-butyl-2H-pyrazol-3-yl)-2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionamide;
N-(5-cyclopropyl-2H-pyrazol-3-yl)-2-[2-(3,5-difluoro-phenyl)-acetylamino]- propionamide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-pentanoic acid (5-furan-2-yl-2H-pyrazol-3-yl)- amide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-pentanoic acid (5-thiophen-2-yl-2H-pyrazol-3- yl)-amide; 2-[2-(3,5-difluoro-phenyl)-acetylamino]-pentanoic acid (5-tert-butyl- 2H-pyrazol-3-yl)-amide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-pentanoic acid [5-(4-chloro-phenyl)-2H- pyrazol-3-yl]-amide; N-(5-tert-butyl-2H-pyrazol-3-yl)-2-[2-(3,5-difluoro-phenyl)-acetylamino]-3-methyl- butyramide;
1-[2-(3,5-difluoro-phenyl)-acetylamino]- cyclopropanecarboxylic acid (5-tert-buty!-2H- pyrazol-3-yl)- amide;
1 -[2-(3,5-difluoro-phenyl)-acetylamino]-cyclopropanecarboxylic acid (5-furan-2-yl-2H- pyrazol-3-yl)- amide;
N-(5-biphenyl-4-yl-2H-pyrazol-3-yl)-2-[2-(3,5-difluoro-phenyl)-acetylamino]- propionamide;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-[5-(3',4'-dimethyl-biphenyl-4-yl)-2H-pyrazol- 3-yl]-propionamide; 2-[2-(3,5-difluoro-phenyl)-acetylamino]-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)- amide;
2-phenylmethanesulfonylamino-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
2-(4-fluoro-phenylmethanesulfonylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
2-(2-nitro-phenylmethanesulfonylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide; 2-phenylmethanesulfonylamino-pentanoic acid (5-tert-butyl-2H-pyrazol-3-yl)-amide;
2-(4-fluoro-phenylmethanesulfonylamino)-pentanoic acid (5-tert-butyl- 2H-pyrazol-3-yl)-amide;
N-(5-tert-butyl-2H-pyrazol-3-yl)-2-phenylmethanesulfonylamino-propionamide;
2-p-tolylmethanesulfonylamino-pentanoic acid (5-tert-butyl-2H-pyrazol-3-yl)-amide; 2-phenylmethanesulfonylamino-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
2-(decane-1 -sulfonylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
2-(biphenyl-4-sulfonylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
2-(4-chloro-phenylmethanesulfonylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)- amide; 2-benzenesulfonylamino-4-methylsulfanyl-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
2-(4-fluoro-phenylmethanesulfonylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)- amide;
2-(4,5-dichloro-thiophene-2-sulfonylamino)-4-methylsuIfanyl-N-(5-phenyl-2H-pyrazol- 3-yl)-butyramide; and 2-(4-chloro-phenylmethanesuIfonylamino)-pentanoic acid (5-tert-butyl-2H-pyrazol-3- yl)-amide; 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid benzyl-methyl-amide;
3,7-Dimethyl-oct-6-enoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide;
2-[2-(1-Benzyl-piperidin-3-yl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide; 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid dibutylamide;
3-{[1-(5-Phenyl-2H-pyrazol-3-ylcarbamoyl)-propylcarbamoyl]-methyl}-piperidine-1- carboxylic acid tert-butyl ester;
3-{[1-(5-Phenyl-2H-pyrazol-3-ylcarbamoyl)-propylcarbamoyl]-methyl}-piperidine-1- carboxylic acid tert-butyl ester;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid ethyl-methyl-amide;
2-[2-(3-Chloro-phenyl)-acetylamino]-pentanoic acid [5-(4-chIoro-phenyl)-2H-pyrazol- 3-yl]-amide; 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-[5-(4-phenyl-piperazine-1 -carbonyl)-2H- pyrazol-3-yl]-butyramide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-[5-(2-hydroxymethyl-pyrrolidine-1- carbonyl)-2H-pyrazol-3-yl]-butyramide;
2-(2-Cyclohexyl-2-hydroxy-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)- amide;
2-(2-Cyclohexyl-2-hydroxy-acetylamino)-pentanoic acid (5-phenyI-2H-pyrazol-3-yl)- amide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-[5-(2,6-dimethyl-morpholine-4-carbonyl)- 2H-pyrazol-3-yl]-butyramide; 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid (2-hydroxy-ethyl)-propyl-amide;
1-(5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carbonyl)- piperidine-3-carboxyIic acid ethyl ester;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid (2,2-dimethoxy-ethyl)-methyl-amide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid diethylamide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid diisobutylamide; 3,7-Dimethyl-oct-6-enoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyI]-amide;
3,7-Dimethyl-oct-6-enoic acid [1 -(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide; 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid dibenzylamide;
2-[2-(3,5-Difluoro-phenyI)-acetylamino]-N-[5-(2-ethyl-piperidine-1-carbonyl)-2H- pyrazol-3-yl]-butyramide; 5-{2-[2-(3,5-Difluoro-phenyI)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid benzyl-ethyl-amide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid butyl-methyl-amide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylam.no]-butyrylamino}-1 H-pyrazole-3-carboxylic acid dihexylamide;
2-[2-(2,3-Difluoro-phenyI)-2-hydroxy-acetylamino]-pentanoic acid (5-phenyl-2H- pyrazol-3-yl)-amide;
2-[2-(1-Benzenesulfonyl-piperidin-3-yl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- butyramide; 2-[2-(1-Acetyl-piperidin-3-yl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid dipropylamide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-[5-(1-methyl-1 H-benzoimidazol-2-yl)-2H- pyrazol-3-yl]-butyramide; 2-[2-(5-Bromo-pyridin-3-yl)-acetylamino]-pentanoic acid [5-(4-chloro-phenyl)-2H- pyrazol-3-yl]-amide;
2-[2-(3-Trifluoromethyl-phenyl)-acetylamino]-pentanoic acid [5-(4-chloro-phenyl)-2H- pyrazol-3-yrj-amide;
2-[2-(3-Methoxy-phenyl)-acetylamino]-pentanoic acid [5-(4-chloro-phenyl)-2H-pyrazol- 3-yI]-amide;
3-{1-[5-(4-Chloro-phenyl)-2H-pyrazol-3-ylcarbamoyl]-butylcarbamoyl}-5-methyl-2- propyl-hexanoic acid tert-butyl ester;
N-(5-Phenyl-2H-pyrazol-3-yl)-2-[2-(5-phenyl-pyridin-3-yl)-acetylamino]-butyramide;
N-(5-Phenyl-2H-pyrazol-3-yl)-2-(2-piperidin-1-yl-acetylamino)-butyramide 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid dipentylamide;
2-Hydroxy-hexanoic acid [1 -(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide;
2-[2-(2-Chloro-phenyl)-2-hydroxy-acetylamino]-pentanoic acid (5-phenyl-2H-pyrazol- 3-yI)-amide; 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoic acid (2H-pyrazol-3-yl)-amide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-[5-(5,6,7,8-tetrahydro- [1 ,2,4]triazolo[4,3- a]pyridin-3-yl)-2H-pyrazol-3-yl]-butyramide; 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-3,3-dimethyl-N-(5-phenyl-2H-pyrazol-3-yl)- butyramide;
2-(2-Hydroxy-3-methyl-butyrylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)- amide; 2-[2-(5-o-Tolyl-pyridin-3-yl)-acetylamino]-pentanoic acid [5-(4-chloro-phenyl)-2H- pyrazol-3-yl]-amide;
2-Hydroxy-3-methyl-N-[1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propyl]-butyramide;
2-[2-(2-Oxo-azepan-3-yl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
2-[2-(2-Oxo-azepan-3-yl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide; 3,7-Dimethyl-octa-2,6-dienoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butylj- amide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoic acid (5-methyl-2H-pyrazol-3-yl)- amide; and
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-hexanoic acid (5-phenyl-2H-pyrazol-3-yl)- amide; and pharmaceutically acceptable salts thereof.
12. A compound according to claim 11 selected from the group consisting of:
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-(5-furan-2-yl-2H-pyrazol-3-yl)- propionamide;
N-(5-tert-Butyl-2H-pyrazol-3-yl)-2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionamide;
N-(5-Cyclopropyl-2H-pyrazol-3-yl)-2-[2-(3,5-difluoro-phenyl)-acetylaminoj- propionamide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)- amide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)- amide;
2-[2-(3,5-Difluoro-phenyl)-acetylaminoj-pentanoic acid (5-furan-2-yl-2H-pyrazol-3-yl)- amide; 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoic acid (5-thiophen-2-yl-2H-pyrazol-3- yl)-amide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoic acid (5-cyclopropyl-2H-pyrazol-3- yl)-amide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoic acid [5-(4-chloro-phenyl)-2H- pyrazol-3-yl]-amide;
2-Phenylacetylamino-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
2-[2-(3-Fluoro-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide; 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide;
2-[2-(4-Fluoro-3-trifluoromethyl-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide; 2-[2-(3-Phenoxy-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pent-4-enoic acid (5-phenyl-2H-pyrazol-3-yl)- amide;
2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-4-methylsulfanyl-N- (5-phenyl-2H- pyrazol-3-yl)-butyramide; 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- butyramide;
2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- butyramide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid ethyl ester;
5-[2-(2-Hydroxy-4-methyl-pentanoylamino)-butyrylamino]-1 H-pyrazole-3-carboxylic acid ethyl ester;
5-{2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-butyrylamino}-1 H-pyrazoIe-3- carboxylic acid ethyl ester; 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)- propionamide;
N-(5-Phenyl-2H-pyrazol-3-yl)-2-(2-pyridin-3-yl-acetylamino)-butyramide; 2-[2-(5-Bromo-pyridin-3-yl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide; 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid butyl-ethyl-amide;
2-[2-(3-Phenoxy-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide; 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid piperidin-1-ylamide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetyIamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid cyclohexyl-ethyl-amide;
2-(2-Cyclohexyl-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide; 4-Methyl-pentanoic acid [1 -(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide; 3-Methyl-pentanoic acid [1 -(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyI]-amide; 2-(2-CycIopentyl-acetyIamino)-pentanoic acid (5-phenyI-2H-pyrazol-3-yl)-amide; 2-(2-Cyclopropyl-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yI)-amide;
2-[2-(3-Chloro-phenyl)-acetylamino]-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide; 2-[2-(3-Bromo-phenyl)-acetylamino]-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide; 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid benzyl-methyl-amide;
3,7-Dimethyl-oct-6-enoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid dibutylamide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid ethyl-methyl-amide;
2-(2-Cyclohexyl-2-hydroxy-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)- amide; 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-[5-(2,6-dimethyl-morpholine-4-carbonyl)-
2H-pyrazol-3-yl]-butyramide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazoIe-3-carboxylic acid (2-hydroxy-ethyl)-propyl-amide;
1-(5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carbonyl)- piperidine-3-carboxylic acid ethyl ester;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid (2,2-dimethoxy-ethyI)-methyl-amide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazoIe-3-carboxylic acid diisobutylamide; 3,7-Dimethyl-oct-6-enoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid dibenzylamide;
2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-[5-(2-ethyl-piperidine-1-carbonyl)-2H- pyrazol-3-yl]-butyramide; 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid benzyl-ethyl-amide;
5-{2-[2-(3,5-Diflubro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid butyl-methyl-amide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid dihexylamide;
2-[2-(2,3-Difluoro-phenyl)-2-hydroxy-acetylamino]-pentanoic acid (5-phenyl-2H- pyrazol-3-yl)-amide;
2-[2-(1-Acetyl-piperidin-3-yl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1 H-pyrazole-3-carboxylic acid dipropylamide;
N-(5-Phenyl-2H-pyrazol-3-yl)-2-[2-(5-phenyl-pyridin-3-yl)-acetylamino]-butyramide; 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid dipentylamide;
2-[2-(5-o-Tolyl-pyridin-3-yl)-acetylamino]-pentanoic acid [5-(4-chloro-phenyl)-2H- pyrazol-3-yl]-amide; and 2-Hydroxy-3-methyl-N-[1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-ethyl]-Butyramide; and pharmaceutically acceptable salts thereof.
13. A pharmaceutical composition for treating in a mammal a disease or condition associated with Aβ-peptide production, which pharmaceutical composition comprises a compound according to any of Claims 1-12 in an amount effective in inhibiting Aβ-production, or b) in an amount effective in inhibiting said disease or condition, and a pharmaceutically acceptable carrier.
14. A method for treating in a mammal a disease or condition selected from Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis, cerebral amyloid angiopathy, a prion-mediated disease, inclusion body myositis, stroke, and Down's Syndrome, which method comprises administering to said mammal a) an amount of a compound according to any of Claims 1-12 effective in inhibiting Aβ-production, or b) an amount of a compound according to any of Claims 1-12 effective in treating said disease or condition.
15. A method for treating dementia, including Alzheimer's disease, in a mammal, which method comprises administering to the mammal an effective amount of a compound according to any of Claims 1-12 either alone or in combination with another drug, either separately or as part of a single pharmaceutical composition, wherein the other drug is selected from a memory enhancement agent, an antidepressant agent, an anxiolytic, an antipsychotic agent, a sleep disorder agent, an anti-inflammatory agent, an anti-oxidant agent, a cholesterol modulating agent, or an anti-hypertension agent.
PCT/IB2003/004252 2002-10-09 2003-09-26 Pyrazole compounds for treatment of neurodegenerative disorders Ceased WO2004033434A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BR0315158-1A BR0315158A (en) 2002-10-09 2003-09-26 Pyrazole Compounds for the Treatment of Neurodegenative Disorders
CA002501799A CA2501799C (en) 2002-10-09 2003-09-26 Pyrazole compounds for treatment of neurodegenerative disorders
AU2003263518A AU2003263518A1 (en) 2002-10-09 2003-09-26 Pyrazole compounds for treatment of neurodegenerative disorders
MXPA05003432A MXPA05003432A (en) 2002-10-09 2003-09-26 Pyrazole compounds for treatment of neurodegenerative disorders.
EP03807922A EP1551809A1 (en) 2002-10-09 2003-09-26 Pyrazole compounds for treatment of neurodegenerative disorders
JP2004542713A JP2006504725A (en) 2002-10-09 2003-09-26 Pyrazole compounds for the treatment of neurodegenerative disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41715102P 2002-10-09 2002-10-09
US60/417,151 2002-10-09

Publications (1)

Publication Number Publication Date
WO2004033434A1 true WO2004033434A1 (en) 2004-04-22

Family

ID=32093974

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/004252 Ceased WO2004033434A1 (en) 2002-10-09 2003-09-26 Pyrazole compounds for treatment of neurodegenerative disorders

Country Status (8)

Country Link
US (2) US7238721B2 (en)
EP (1) EP1551809A1 (en)
JP (1) JP2006504725A (en)
AU (1) AU2003263518A1 (en)
BR (1) BR0315158A (en)
CA (1) CA2501799C (en)
MX (1) MXPA05003432A (en)
WO (1) WO2004033434A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004098590A1 (en) * 2003-05-02 2004-11-18 Elan Pharmaceuticals, Inc. 4-bromo-5- (2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-(aminocarbonyl) eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
WO2004099200A1 (en) * 2003-05-12 2004-11-18 Pfizer Products Inc. Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders
WO2004098589A1 (en) * 2003-05-02 2004-11-18 Elan Pharmaceuticals, Inc. 4- bromo - 5 - (2- chloro - benzoylamino) - 1h - pyrazole - 3 - carboxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
WO2005095361A1 (en) * 2004-04-01 2005-10-13 Pfizer Products Inc. Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders
WO2005095348A3 (en) * 2004-04-01 2006-03-23 Pfizer Prod Inc Pyrazole-amine compounds for the treatment of neurodegenerative disorders
WO2008046527A1 (en) * 2006-10-17 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Acylaminopyrazoles for treating cardiovascular diseases
US7759382B2 (en) 2003-06-05 2010-07-20 Elan Pharmaceuticals, Inc. Acylated amino acid amidyl pyrazoles and related compounds
CN102119047A (en) * 2008-07-15 2011-07-06 诺瓦提斯公司 Heteroaryl derivatives as DGAT1 inhibitors
CN103781472A (en) * 2011-04-13 2014-05-07 纽泰克制药有限公司 Synthesis and application of propofol side derivatives
EP2626352A4 (en) * 2010-08-31 2014-06-04 Obschestvo S Ogranichennoy Otvetstvennostju Biopharm Memorien Heterocyclic low-molecular sapp mimetics, a pharmaceutical composition and methods for producing and using same
AU2013305759B2 (en) * 2012-08-23 2017-09-28 Janssen Biopharma, Inc. Compounds for the treatment of paramoxyvirus viral infections
CN114957127A (en) * 2022-05-24 2022-08-30 深圳大学 A kind of glutaminyl cyclase inhibitor and preparation method and application thereof

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004033434A1 (en) * 2002-10-09 2004-04-22 Pfizer Products Inc. Pyrazole compounds for treatment of neurodegenerative disorders
WO2004099155A2 (en) * 2003-05-02 2004-11-18 Elan Pharmaceuticals, Inc. 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivates and related compounds as bradykinin b1 receptor antagonists for the treatment of inflamatory diseases
MXPA06001480A (en) * 2003-08-06 2006-05-15 Pfizer Prod Inc Oxazole compounds for the treatment of neurodegenerative disorders.
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
CN1934091B (en) * 2004-03-23 2012-02-08 辉瑞产品公司 imidazole compounds for the treatment of neurodegenerative disorders
JP2008535790A (en) * 2005-03-03 2008-09-04 サートリス ファーマシューティカルズ， インコーポレイテッド N-phenylbenzamide derivatives which are sirtuin modulators
US7855289B2 (en) * 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8093401B2 (en) * 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) * 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
EP1910385B1 (en) * 2005-08-04 2013-07-24 Sirtris Pharmaceuticals, Inc. Benzothiazoles and thiazolopyridines as sirtuin modulators
WO2007034326A2 (en) * 2005-09-22 2007-03-29 Pfizer Products Inc. Imidazole compounds for the treatment of neurological disorders
TW200916472A (en) * 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
US20090149544A1 (en) * 2007-10-22 2009-06-11 Concert Pharmaceuticals, Inc. Alpha-aminoamide derivatives
JP2011502984A (en) * 2007-11-01 2011-01-27 サートリス ファーマシューティカルズ， インコーポレイテッド Amide derivatives as sirtuin modulators
CA2705138A1 (en) * 2007-11-08 2009-05-14 Sirtris Pharmaceuticals, Inc. Solubilized thiazolopyridines
EP2376502B1 (en) 2008-12-19 2015-06-17 GlaxoSmithKline LLC Thiazolopyridine sirtuin modulating compounds
CN103180297A (en) * 2009-12-11 2013-06-26 基因密码公司 Methods of promoting neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators
UA110688C2 (en) 2012-09-21 2016-01-25 Пфайзер Інк. Bicyclic pirydynony
MX368391B (en) 2015-02-03 2019-09-30 Pfizer Novel cyclopropabenzofuranyl pyridopyrazinediones.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0885890A1 (en) * 1996-02-26 1998-12-23 Sumitomo Pharmaceuticals Company, Limited Sulfonylureidopyrazole derivatives
WO2001012188A1 (en) * 1999-08-12 2001-02-22 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents
WO2002018346A1 (en) * 2000-08-31 2002-03-07 Pfizer Products Inc. Pyrazole derivatives and their use as protein kinase inhibitors
WO2002048114A1 (en) * 2000-11-27 2002-06-20 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
WO2003064396A1 (en) * 2002-02-01 2003-08-07 Elan Pharmaceuticals, Inc. Hydroxyalkanoyl aminopyrazoles and related compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020103185A1 (en) * 2000-08-31 2002-08-01 Sanner Mark A. Pyrazole derivatives
WO2004033434A1 (en) 2002-10-09 2004-04-22 Pfizer Products Inc. Pyrazole compounds for treatment of neurodegenerative disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0885890A1 (en) * 1996-02-26 1998-12-23 Sumitomo Pharmaceuticals Company, Limited Sulfonylureidopyrazole derivatives
WO2001012188A1 (en) * 1999-08-12 2001-02-22 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents
WO2002018346A1 (en) * 2000-08-31 2002-03-07 Pfizer Products Inc. Pyrazole derivatives and their use as protein kinase inhibitors
WO2002048114A1 (en) * 2000-11-27 2002-06-20 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
WO2003064396A1 (en) * 2002-02-01 2003-08-07 Elan Pharmaceuticals, Inc. Hydroxyalkanoyl aminopyrazoles and related compounds

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7417152B2 (en) 2003-05-02 2008-08-26 Elan Pharmaceuticals, Inc. 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases
WO2004098589A1 (en) * 2003-05-02 2004-11-18 Elan Pharmaceuticals, Inc. 4- bromo - 5 - (2- chloro - benzoylamino) - 1h - pyrazole - 3 - carboxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
WO2004098590A1 (en) * 2003-05-02 2004-11-18 Elan Pharmaceuticals, Inc. 4-bromo-5- (2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-(aminocarbonyl) eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
US7432379B2 (en) 2003-05-02 2008-10-07 Elan Pharmaceuticals, Inc. Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
WO2004099200A1 (en) * 2003-05-12 2004-11-18 Pfizer Products Inc. Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders
US7241786B2 (en) 2003-05-12 2007-07-10 Pfizer Inc Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders
EP2511267A1 (en) * 2003-06-05 2012-10-17 Elan Pharmaceuticals Inc. 3-((n-acylated aminoacyl)amino)pyrazoles as inhibitors of beta-amyloid peptide production useful for the treatment of alzheimer's disease
US7759382B2 (en) 2003-06-05 2010-07-20 Elan Pharmaceuticals, Inc. Acylated amino acid amidyl pyrazoles and related compounds
WO2005095361A1 (en) * 2004-04-01 2005-10-13 Pfizer Products Inc. Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders
EP1958939A2 (en) 2004-04-01 2008-08-20 Pfizer Products Inc. Pyrazole-amine compounds for the treatment of neurodegenerative disorders
EP1958939A3 (en) * 2004-04-01 2008-09-10 Pfizer Products Inc. Pyrazole-amine compounds for the treatment of neurodegenerative disorders
US7468386B2 (en) 2004-04-01 2008-12-23 Pfizer Inc. Pyrazole-amine compounds for the treatment of neurodegenerative disorders
US7244757B2 (en) 2004-04-01 2007-07-17 Pfizer Inc Pyrazole-amine compounds for the treatment of neurodegenerative disorders
WO2005095348A3 (en) * 2004-04-01 2006-03-23 Pfizer Prod Inc Pyrazole-amine compounds for the treatment of neurodegenerative disorders
WO2008046527A1 (en) * 2006-10-17 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Acylaminopyrazoles for treating cardiovascular diseases
CN102119047A (en) * 2008-07-15 2011-07-06 诺瓦提斯公司 Heteroaryl derivatives as DGAT1 inhibitors
CN102119047B (en) * 2008-07-15 2014-09-24 诺华股份有限公司 Heteroaryl derivatives as DGAT1 inhibitors
EP2548618A2 (en) 2008-07-15 2013-01-23 Novartis AG Organic compounds
EP2559455A1 (en) 2008-07-15 2013-02-20 Novartis AG Heteroaryl derivatives as DGAT1 inhibitors
US8703761B2 (en) 2008-07-15 2014-04-22 Novartis Ag Organic compounds
EP2380631A1 (en) 2008-07-15 2011-10-26 Novartis AG Heteroaryl derivatives as DGAT1 inhibitors
EP2626352A4 (en) * 2010-08-31 2014-06-04 Obschestvo S Ogranichennoy Otvetstvennostju Biopharm Memorien Heterocyclic low-molecular sapp mimetics, a pharmaceutical composition and methods for producing and using same
CN103781472A (en) * 2011-04-13 2014-05-07 纽泰克制药有限公司 Synthesis and application of propofol side derivatives
CN103781472B (en) * 2011-04-13 2016-08-17 纽泰克制药有限公司 Synthesis and application of propofol side derivatives
AU2013305759B2 (en) * 2012-08-23 2017-09-28 Janssen Biopharma, Inc. Compounds for the treatment of paramoxyvirus viral infections
AU2013305759C1 (en) * 2012-08-23 2018-01-18 Janssen Biopharma, Inc. Compounds for the treatment of paramoxyvirus viral infections
US11014935B2 (en) 2012-08-23 2021-05-25 Janssen Biopharma, Inc. Compounds for the treatment of paramyxovirus viral infections
CN114957127A (en) * 2022-05-24 2022-08-30 深圳大学 A kind of glutaminyl cyclase inhibitor and preparation method and application thereof
CN114957127B (en) * 2022-05-24 2023-08-15 深圳大学 A kind of glutaminyl cyclase inhibitor and its preparation method and application

Also Published As

Publication number Publication date
CA2501799C (en) 2008-06-17
JP2006504725A (en) 2006-02-09
US20070270474A1 (en) 2007-11-22
US7521464B2 (en) 2009-04-21
CA2501799A1 (en) 2004-04-22
EP1551809A1 (en) 2005-07-13
US7238721B2 (en) 2007-07-03
US20040142997A1 (en) 2004-07-22
MXPA05003432A (en) 2005-07-05
AU2003263518A1 (en) 2004-05-04
BR0315158A (en) 2005-08-16

Similar Documents

Publication Publication Date Title
US7521464B2 (en) Pyrazole compounds for treatment of neurodegenerative disorders
KR100814599B1 (en) Imidazole compounds for the treatment of neurodegenerative disorders
RU2114113C1 (en) Pyrazolopyrimidinones, pharmaceutical composition and method of inhibition of cyclic guanosine-3',5'-monophosphate phosphodiesterase
AU2004314287B2 (en) Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the FAAH enzyme
US20040152747A1 (en) Thiazole compounds for treatment of neurodegenerative disorders
JPH05155871A (en) 2-Acylamino-5-thiazole derivatives, processes and compositions
CN107108581A (en) It is used as the tieback heterocyclic carbamate derivatives of potent ROCK inhibitor
JPH03279374A (en) Substituted acylaminothiazole in heterocyclic ring
EP1097921A1 (en) Phenylhydrazines
US7241786B2 (en) Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders
BR112021000650A2 (en) HETEROAROMATIC COMPOUNDS AS VANINE INHIBITORS
JP2019532972A (en) Bicyclic heteroaryl derivatives
CA3120037A1 (en) Heteroaromatic compounds as vanin inhibitors
CZ289484B6 (en) Triazole derivative, process of its preparation, intermediate for this preparation process, pharmaceutical composition in which the derivative is comprised and use of the derivative for preparing medicaments
PT1603917E (en) Immunomodulating heterocyclic compounds
BE1009571A3 (en) Piperidine derivatives, method for their production and pharmaceutical compositions containing.
US5217971A (en) Thiazole compounds and pharmaceutical composition comprising the same
CA3153083A1 (en) Indazole carboxamides as kinase inhibitors
US20080108675A1 (en) Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
US7112599B2 (en) Oxazole compounds for the treatment of neurodegenerative disorders
CN113754635A (en) Fused ring compound and preparation method and application thereof
CN103508957B (en) Hydroxyethyl pyrazole compound or aminoethyl pyrazole compound, preparation method and use thereof
KR101817925B1 (en) Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
JP2881688B2 (en) Sulfonamide derivative
JP2936324B2 (en) Sulfonamide derivative

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/003432

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2501799

Country of ref document: CA

Ref document number: 2004542713

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003807922

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003807922

Country of ref document: EP